<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36399343</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association of Pregnancy Characteristics and Maternal Mortality With Amniotic Fluid Embolism.</ArticleTitle><Pagination><StartPage>e2242842</StartPage><MedlinePgn>e2242842</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2242842</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.42842</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Amniotic fluid embolism (AFE) is an uncommon pregnancy complication but is associated with high maternal mortality. Because of the rarity of AFE, associated risks factors and maternal outcomes have been relatively understudied.</AbstractText><AbstractText Label="OBJECTIVE">To examine the clinical, pregnancy, and delivery characteristics and the maternal outcomes related to AFE in a recent period in the US.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This retrospective cohort study examined hospital deliveries from January 1, 2016, to December 31, 2019, from the Healthcare Cost and Utilization Project's National Inpatient Sample.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was clinical, pregnancy, and delivery characteristics of AFE, assessed with a multivariable binary logistic regression model. The coprimary outcome was failure to rescue, defined as maternal mortality after AFE. Associations with other severe maternal morbidity indicators and failure to rescue per clinical and pregnancy characteristics were also assessed.</AbstractText><AbstractText Label="RESULTS">A total of 14&#x202f;684&#x202f;135 deliveries were examined, with AFE diagnosed in 880 women, corresponding to an incidence rate of 6.0 per 100&#x202f;000 deliveries. The cohort-level median patient age was 29 years (IQR, 25-33 years). In a multivariable analysis, (1) patient factors of older age, Asian and Black race, Western US region, pregestational hypertension, asthma, illicit substance use, and grand multiparity; (2) pregnancy factors of placental accreta spectrum (PAS), placental abruption, uterine rupture, polyhydramnios, chorioamnionitis, preeclampsia, fetal growth restriction, and fetal demise; and (3) delivery factors of early gestational age, cervical ripening, cesarean delivery, operative delivery, and manual removal were associated with AFE. Among these characteristics, PAS had the largest association with AFE (adjusted odds ratio [aOR], 10.01; 95% CI, 7.03-14.24). When stratified by the PAS subtypes, more severe forms of PAS had a greater association with AFE (aOR for increta and percreta, 17.35; 95% CI, 10.21-28.48; and aOR for accreta, 7.62; 95% CI, 4.83-12.01). Patients who had AFE were more likely to have coagulopathy (aOR, 24.68; 95% CI, 19.38-31.44), cardiac arrest (aOR, 24.56; 95% CI, 17.84-33.81), and adult respiratory distress syndrome (aOR, 10.72; 95% CI, 8.09-14.20). The failure-to-rescue rate after AFE was 17.0% overall. However, the failure-to-rescue rate exceeded 30% when AFE co-occurred with other severe maternal morbidity indicators: 45.8% for AFE, cardiac arrest, and coagulopathy; 43.2% for AFE, shock, and cardiac rhythm conversion; and 38.6% for AFE, cardiac arrest, coagulopathy, and shock. The failure-to-rescue rate after AFE also exceeded 30% when AFE occurred in the setting of placental pathology: 42.9% for AFE and PAS and 31.3% for AFE and placental abruption.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This contemporaneous, national-level analysis validated previously known risk factors for AFE and confirmed the dismal outcomes of pregnancy complicated by AFE. The association between PAS and AFE, which was not previously reported, warrants further investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazza</LastName><ForeName>Genevieve R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youssefzadeh</LastName><ForeName>Ariane C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klar</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Freiburg Faculty of Medicine, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunze</LastName><ForeName>Mirjam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Freiburg Faculty of Medicine, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuzaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelbaum</LastName><ForeName>Rachel S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Reproductive Endocrinology &amp; Infertility, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouzounian</LastName><ForeName>Joseph G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuo</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Netw Open. 2022 Nov 1;5(11):e2242850. doi: 10.1001/jamanetworkopen.2022.42850.</RefSource><PMID Version="1">36399346</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="Y">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008428" MajorTopicYN="N">Maternal Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000037" MajorTopicYN="Y">Abruptio Placentae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010920" MajorTopicYN="N">Placenta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010298" MajorTopicYN="N">Parity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="Y">Heart Arrest</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Klar reported receiving personal fees from Cooper Surgical and KLS Martin outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36399343</ArticleId><ArticleId IdType="pmc">PMC9675004</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.42842</ArticleId><ArticleId IdType="pii">2798663</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention. Pregnancy Mortality Surveillance System. Accessed May 14, 2022. https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm</Citation></Reference><Reference><Citation>Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201(5):445.e1-445.e13. doi:10.1016/j.ajog.2009.04.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2009.04.052</ArticleId><ArticleId IdType="pmc">PMC3401570</ArticleId><ArticleId IdType="pubmed">19879393</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008;199(1):36.e1-36.e5. doi:10.1016/j.ajog.2008.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2008.03.007</ArticleId><ArticleId IdType="pubmed">18455140</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG. 2016;123(1):100-109. doi:10.1111/1471-0528.13300</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.13300</ArticleId><ArticleId IdType="pubmed">25683758</ArticleId></ArticleIdList></Reference><Reference><Citation>Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol. 2008;199(1):49.e1-49.e8. doi:10.1016/j.ajog.2007.11.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2007.11.061</ArticleId><ArticleId IdType="pubmed">18295171</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick KE, van den Akker T, Bloemenkamp KWM, et al. . Risk factors, management, and outcomes of amniotic fluid embolism: a multicountry, population-based cohort and nested case-control study. PLoS Med. 2019;16(11):e1002962. doi:10.1371/journal.pmed.1002962</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002962</ArticleId><ArticleId IdType="pmc">PMC6850527</ArticleId><ArticleId IdType="pubmed">31714909</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight M, Berg C, Brocklehurst P, et al. . Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth. 2012;12:7. doi:10.1186/1471-2393-12-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2393-12-7</ArticleId><ArticleId IdType="pmc">PMC3305555</ArticleId><ArticleId IdType="pubmed">22325370</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight M, Tuffnell D, Brocklehurst P, Spark P, Kurinczuk JJ; UK Obstetric Surveillance System . Incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol. 2010;115(5):910-917. doi:10.1097/AOG.0b013e3181d9f629</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e3181d9f629</ArticleId><ArticleId IdType="pubmed">20410762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer MS, Rouleau J, Baskett TF, Joseph KS; Maternal Health Study Group of the Canadian Perinatal Surveillance System . Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet. 2006;368(9545):1444-1448. doi:10.1016/S0140-6736(06)69607-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69607-4</ArticleId><ArticleId IdType="pubmed">17055946</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts CL, Algert CS, Knight M, Morris JM. Amniotic fluid embolism in an Australian population-based cohort. BJOG. 2010;117(11):1417-1421. doi:10.1111/j.1471-0528.2010.02656.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-0528.2010.02656.x</ArticleId><ArticleId IdType="pubmed">21126320</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco LD, Saade G, Hankins GD, Clark SL; Society for Maternal-Fetal Medicine (SMFM) . Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol. 2016;215(2):B16-B24. doi:10.1016/j.ajog.2016.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2016.03.012</ArticleId><ArticleId IdType="pubmed">26987420</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SL, Romero R, Dildy GA, et al. . Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 2016;215(4):408-412. doi:10.1016/j.ajog.2016.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2016.06.037</ArticleId><ArticleId IdType="pmc">PMC5072279</ArticleId><ArticleId IdType="pubmed">27372270</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford IA, Moaddab A, Dildy GA, et al. . Amniotic fluid embolism syndrome: analysis of the Unites States International Registry. Am J Obstet Gynecol MFM. 2020;2(2):100083. doi:10.1016/j.ajogmf.2019.100083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajogmf.2019.100083</ArticleId><ArticleId IdType="pmc">PMC8500673</ArticleId><ArticleId IdType="pubmed">33345954</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2014;123(2, pt 1):337-348. doi:10.1097/AOG.0000000000000107</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000000107</ArticleId><ArticleId IdType="pubmed">24402585</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshirsaz AA, Clark SL. Amniotic fluid embolism. Obstet Gynecol Clin North Am. 2016;43(4):779-790. doi:10.1016/j.ogc.2016.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ogc.2016.07.001</ArticleId><ArticleId IdType="pubmed">27816160</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality. Overview of the National (Nationwide) Inpatient Sample . Accessed May 8, 2022. https://www.hcup-us.ahrq.gov/nisoverview.jsp</Citation></Reference><Reference><Citation>Ghaferi AA, Schwartz TA, Pawlik TM. STROBE reporting guidelines for observational studies. JAMA Surg. 2021;156(6):577-578. doi:10.1001/jamasurg.2021.0528</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2021.0528</ArticleId><ArticleId IdType="pubmed">33825815</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. How Does CDC Identify Severe Maternal Morbidity? Accessed May 8, 2022. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/smm/severe-morbidity-ICD.htm</Citation></Reference><Reference><Citation>Matsuo K, Mandelbaum RS, Matsuzaki S, et al. . Decreasing failure-to-rescue from severe maternal morbidity at cesarean delivery: recent US trends. JAMA Surg. 2021;156(6):585-587. doi:10.1001/jamasurg.2021.0600</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2021.0600</ArticleId><ArticleId IdType="pmc">PMC8060881</ArticleId><ArticleId IdType="pubmed">33881490</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott M. ICD-10-PCS coding advice for labor induction. CMQCC. Accessed May 10, 2022. https://www.cmqcc.org/sites/default/files/ICD10%20Labor%20Induction%20FINAL_8.3.16.pdf</Citation></Reference><Reference><Citation>Greenland S, Daniel R, Pearce N. Outcome modelling strategies in epidemiology: traditional methods and basic alternatives. Int J Epidemiol. 2016;45(2):565-575. doi:10.1093/ije/dyw040</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw040</ArticleId><ArticleId IdType="pmc">PMC4864881</ArticleId><ArticleId IdType="pubmed">27097747</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo K, Violette CJ, Mandelbaum RS, et al. . Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia. Am J Obstet Gynecol. 2022;227(2):255.e1-255.e18. doi:10.1016/j.ajog.2022.04.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2022.04.032</ArticleId><ArticleId IdType="pubmed">35487326</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver RM, Branch DW. Placenta accreta spectrum. N Engl J Med. 2018;378(16):1529-1536. doi:10.1056/NEJMcp1709324</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1709324</ArticleId><ArticleId IdType="pubmed">29669225</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson RG, Ruggieri J, Siddiqui MM. Amniotic fluid embolism: definitive diagnosis in a survivor. Am Rev Respir Dis. 1979;120(1):187-192. doi:10.1164/arrd.1979.120.1.187</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/arrd.1979.120.1.187</ArticleId><ArticleId IdType="pubmed">380421</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbison L, Bell L. Anaphylactoid syndrome after intrauterine pressure catheter placement. Obstet Gynecol. 2010;115(2, pt 2):407-408. doi:10.1097/AOG.0b013e3181b5c8cc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e3181b5c8cc</ArticleId><ArticleId IdType="pubmed">20093860</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo K, Lynch MA, Kopelman JN, Atlas RO. Anaphylactoid syndrome of pregnancy immediately after intrauterine pressure catheter placement. Am J Obstet Gynecol. 2008;198(2):e8-e9. doi:10.1016/j.ajog.2007.09.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2007.09.035</ArticleId><ArticleId IdType="pubmed">18068141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinn JJ, Eisenberg E, Artis Dickerson S, et al. . Maternal mortality in the United States: research gaps, opportunities, and priorities. Am J Obstet Gynecol. 2020;223(4):486-492.e6. doi:10.1016/j.ajog.2020.07.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2020.07.021</ArticleId><ArticleId IdType="pmc">PMC7564012</ArticleId><ArticleId IdType="pubmed">32682858</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CA, Montgomery DM, Toner LE, Dildy GA; Patient Safety and Quality Committee, Society for Maternal-Fetal Medicine . Society for Maternal-Fetal Medicine Special Statement: checklist for initial management of amniotic fluid embolism. Am J Obstet Gynecol. 2021;224(4):B29-B32. doi:10.1016/j.ajog.2021.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2021.01.001</ArticleId><ArticleId IdType="pubmed">33417901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco LD, Clark SL, Klassen M, Hankins GDV. Amniotic fluid embolism: principles of early clinical management. Am J Obstet Gynecol. 2020;222(1):48-52. doi:10.1016/j.ajog.2019.07.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2019.07.036</ArticleId><ArticleId IdType="pubmed">31376394</ArticleId></ArticleIdList></Reference><Reference><Citation>Amodeo S, Cavoretto PI, Seidenari A, et al. . Second trimester uterine arteries pulsatility index is a function of placental pathology and provides insights on stillbirth aetiology: a multicenter matched case-control study. Placenta. 2022;121:7-13. doi:10.1016/j.placenta.2022.02.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.placenta.2022.02.021</ArticleId><ArticleId IdType="pubmed">35245721</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford IA, Moaddab A, Dildy GA, et al. . Evaluation of proposed criteria for research reporting of amniotic fluid embolism. Am J Obstet Gynecol. 2019;220(3):285-287. doi:10.1016/j.ajog.2018.11.1099</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2018.11.1099</ArticleId><ArticleId IdType="pmc">PMC6497410</ArticleId><ArticleId IdType="pubmed">30481492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36307749</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1496-8975</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Canadian journal of anaesthesia = Journal canadien d'anesthesie</Title><ISOAbbreviation>Can J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Echocardiography findings in amniotic fluid embolism: a systematic review of the literature.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>160</EndPage><MedlinePgn>151-160</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12630-022-02343-9</ELocationID><Abstract><AbstractText Label="PURPOSE">Amniotic fluid embolism (AFE) is a leading cause of obstetrical cardiac arrest and maternal morbidity. The pathogenesis of hemodynamic collapse is thought to be from right ventricular (RV) failure; however, there is a paucity of data documenting echocardiography findings in this population. We undertook a systematic review of the literature to evaluate the echocardiography findings in patients with AFE.</AbstractText><AbstractText Label="SOURCES">We retrieved all case reports and case series reporting AFE in Embase and MEDLINE from inception to 20 November 2021. Studies reporting AFE diagnosed by fulfilling at least one of three different proposed AFE criteria and echocardiography findings during hospitalization were included. Patient and echocardiographic data were retrieved, and univariate logistic regression analysis was performed for outcomes of interest. Bias was assessed using the Joanna Briggs Institute clinical appraisal tool for case series.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS">Eighty publications reporting on 84 patients were included in the final review. Fifty-five out of 82 patients with data (67%) showed RV dysfunction, including 11/82 (13%) with biventricular dysfunction; 14/82 (17%) had normal systolic function. No data on RV or left ventricular function were reported for two patients. The presence of RV dysfunction on echocardiography was associated with cardiac arrest (odds ratio [OR], 3.66; 95% confidence interval [CI], 1.39 to 9.67; P = 0.009), and a composite risk of cardiac arrest, maternal death or use of extracorporeal membrane oxygenation (OR, 3.86; 95% CI, 1.43 to 10.4; P = 0.007). A low risk of bias was observed in 15/84 (18%) cases.</AbstractText><AbstractText Label="CONCLUSIONS">Right ventricular dysfunction on echocardiography is a common finding in AFE and is associated with a high risk of cardiac arrest. The finding of RV dysfunction on echocardiography may help diagnose AFE and help triage the highest risk patients with AFE.</AbstractText><AbstractText Label="STUDY REGISTRATION">PROSPERO (CRD42021271323); registered 1 September 2021.</AbstractText><CopyrightInformation>&#xa9; 2022. Canadian Anesthesiologists' Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiseman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Stephen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Jewish General Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Jewish General Hospital, McGill University, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koolian</LastName><ForeName>Maral</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abenhaim</LastName><ForeName>Haim A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Jewish General Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipes</LastName><ForeName>Jed</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3309-7537</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada. jed.lipes@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care, Jewish General Hospital, McGill University, Montr&#xe9;al, QC, Canada. jed.lipes@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Observations &#xe9;chocardiographiques lors d&#x2019;une embolie de liquide amniotique : une revue syst&#xe9;matique de la litt&#xe9;rature.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Anaesth</MedlineTA><NlmUniqueID>8701709</NlmUniqueID><ISSNLinking>0832-610X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="Y">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008428" MajorTopicYN="N">Maternal Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="Y">Heart Arrest</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="UNLABELLED">R&#xe9;SUM&#xe9;: OBJECTIF: L&#x2019;embolie amniotique (EA) est l&#x2019;une des principales causes d&#x2019;arr&#xea;t cardiaque obst&#xe9;trical et de morbidit&#xe9; maternelle. Il est pr&#xe9;sum&#xe9; que la pathogen&#xe8;se du choc h&#xe9;modynamique provient d&#x2019;une d&#xe9;faillance ventriculaire droite (VD). Cependant, il y a peu de donn&#xe9;es documentant les constatations de l&#x2019;examen &#xe9;chocardiographique dans cette population. Nous avons effectu&#xe9; une revue syst&#xe9;matique des donn&#xe9;es probantes visant &#xe0; &#xe9;valuer l&#x2019;utilit&#xe9; de l&#x2019;&#xe9;chocardiographie chez les patientes atteintes d&#x2019;embolie amniotique.</AbstractText><AbstractText Label="SOURCES" NlmCategory="METHODS">Nous avons &#xe9;valu&#xe9; tous les rapports de cas et s&#xe9;ries de cas rapportant une EA dans les bases de donn&#xe9;es Embase et MEDLINE de leur cr&#xe9;ation jusqu&#x2019;au 20 novembre 2021. Les &#xe9;tudes rapportant une EA diagnostiqu&#xe9;e en remplissant au moins l&#x2019;un des trois crit&#xe8;res d&#x2019;EA propos&#xe9;s et les r&#xe9;sultats &#xe9;chocardiographiques pendant l&#x2019;hospitalisation ont &#xe9;t&#xe9; incluses. Les donn&#xe9;es sur les patientes et &#xe9;chocardiographiques ont &#xe9;t&#xe9; collig&#xe9;es, et une analyse de r&#xe9;gression logistique univari&#xe9;e a &#xe9;t&#xe9; effectu&#xe9;e pour les issues cliniques d&#x2019;int&#xe9;r&#xea;t. Le risque de biais a &#xe9;t&#xe9; &#xe9;valu&#xe9; &#xe0; l&#x2019;aide de l&#x2019;outil d&#x2019;&#xe9;valuation clinique de l&#x2019;Institut Joanna Briggs pour les s&#xe9;ries de cas.</AbstractText><AbstractText Label="CONSTATATIONS PRINCIPALES" NlmCategory="UNASSIGNED">Quatre-vingts publications incluant 84 patientes ont &#xe9;t&#xe9; incluses dans la revue finale. Cinquante-cinq des 82 patientes pr&#xe9;sentant des donn&#xe9;es (67&#xa0;%) avaient une dysfonction du VD incluant 11/82 (13&#xa0;%) avec une dysfonction biventriculaire. Quatorze patientes sur 82 (17 %) avaient une fonction systolique normale. Aucune donn&#xe9;e sur la fonction du ventricule droit ou gauche n&#x2019;a &#xe9;t&#xe9; rapport&#xe9;e pour deux patientes. La pr&#xe9;sence d&#x2019;une dysfonction du VD &#xe0; l&#x2019;&#xe9;chocardiographie &#xe9;tait associ&#xe9;e &#xe0; un arr&#xea;t cardiaque (rapport de cotes [RC], 3,66; intervalle de confiance &#xe0; 95 % [IC], 1,39 &#xe0; 9,67; P = 0,009), et &#xe0; un risque composite d&#x2019;arr&#xea;t cardiaque, de d&#xe9;c&#xe8;s maternel ou d&#x2019;utilisation de l&#x2019;oxyg&#xe9;nation par membrane extracorporelle (ECMO) (RC, 3,86; IC 95 %, 1,43 &#xe0; 10,4; P = 0,007). Un faible risque de biais a &#xe9;t&#xe9; observ&#xe9; dans 15/84 (18&#xa0;%) des cas.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">La dysfonction ventriculaire droite &#xe0; l&#x2019;&#xe9;chocardiographie est une constatation courante dans l&#x2019;embolie amniotique et est associ&#xe9;e &#xe0; un risque &#xe9;lev&#xe9; d&#x2019;arr&#xea;t cardiaque. La d&#xe9;couverte d&#x2019;une dysfonction du VD &#xe0; l&#x2019;&#xe9;chocardiographie peut aider &#xe0; diagnostiquer l&#x2019;embolie amniotique et &#xe0; identifier les patientes atteintes d&#x2019;embolie amniotique les plus &#xe0; risque. ENREGISTREMENT DE L&#x2019;&#xe9;TUD: PROSPERO (CRD42021271323); enregistr&#xe9;e le 1er septembre 2021.</AbstractText><CopyrightInformation>&#xa9; 2022. Canadian Anesthesiologists' Society.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">POCUS</Keyword><Keyword MajorTopicYN="N">amniotic fluid embolism</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">maternal cardiac arrest</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>23</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36307749</ArticleId><ArticleId IdType="doi">10.1007/s12630-022-02343-9</ArticleId><ArticleId IdType="pii">10.1007/s12630-022-02343-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013; 209: e1&#x2013;7. https://doi.org/10.1016/j.ajog.2013.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2013.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshirsaz AA, Clark SL. Amniotic fluid embolism. Obstet Gynecol Clin North Am 2016; 43: 779&#x2013;90. https://doi.org/10.1016/j.ogc.2016.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ogc.2016.07.001</ArticleId><ArticleId IdType="pubmed">27816160</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhyre JM. Maternal mortality. Curr Opin Anaesthesiol 2012; 25: 277&#x2013;85. https://doi.org/10.1097/aco.0b013e3283530580</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/aco.0b013e3283530580</ArticleId><ArticleId IdType="pubmed">22459982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito F, Akasaka J, Koike N, Uekuri C, Shigemitsu A, Kobayashi H. Incidence, diagnosis and pathophysiology of amniotic fluid embolism. J Obstet Gynaecol 2014; 34: 580&#x2013;4. https://doi.org/10.3109/01443615.2014.919996</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01443615.2014.919996</ArticleId><ArticleId IdType="pubmed">24865116</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SL, Romero R, Dildy GA, et al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol 2016; 215: 408&#x2013;12. https://doi.org/10.1016/j.ajog.2016.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2016.06.037</ArticleId><ArticleId IdType="pubmed">27372270</ArticleId><ArticleId IdType="pmc">5072279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanayama N, Tamura N. Amniotic fluid embolism: pathophysiology and new strategies for management. J Obstet Gynaecol Res 2014; 40: 1507&#x2013;17. https://doi.org/10.1111/jog.12428</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jog.12428</ArticleId><ArticleId IdType="pubmed">24888909</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG 2016; 123: 100&#x2013;9. https://doi.org/10.1111/1471-0528.13300</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.13300</ArticleId><ArticleId IdType="pubmed">25683758</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford IA, Moaddab A, Dildy GA, et al. Evaluation of proposed criteria for research reporting of amniotic fluid embolism. Am J Obstet Gynecol 2019; 220: 285&#x2013;7. https://doi.org/10.1016/j.ajog.2018.11.1099</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2018.11.1099</ArticleId><ArticleId IdType="pubmed">30481492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi H, Akasaka J, Naruse K, et al. Comparison of the different definition criteria for the diagnosis of amniotic fluid embolism. J Clin Diagn Res 2017; 11: QC18&#x2013;21. https://doi.org/10.7860/jcdr/2017/26746.10283</Citation></Reference><Reference><Citation>Ponzio-Klijanienko A, Vincent-Rohfritsch A, Girault A, Le Ray C, Goffinet F, Bonnet MP. Evaluation of the 4 diagnosis criteria proposed by the SMFM and the AFE foundation for amniotic fluid embolism in a monocentric population. J Gynecol Obstet Hum Reprod 2020; 49: 101821. https://doi.org/10.1016/j.jogoh.2020.101821</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jogoh.2020.101821</ArticleId><ArticleId IdType="pubmed">32474192</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson AJ, Greer IA. Non-haemorrhagic obstetric shock. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 19&#x2013;41. https://doi.org/10.1053/beog.1999.0061</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/beog.1999.0061</ArticleId><ArticleId IdType="pubmed">10789258</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SL. A biomarker for amniotic fluid embolism: the search continues. BJOG 2021; 128: 1974. https://doi.org/10.1111/1471-0528.16833</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.16833</ArticleId><ArticleId IdType="pubmed">34228892</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard C, Yang S, Koolian M, Shear R, Rudski L, Lipes J. The role of echocardiography in amniotic fluid embolism: a case series and review of the literature. Can J Anesth 2021; 68: 1541&#x2013;8. https://doi.org/10.1007/s12630-021-02065-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-021-02065-4</ArticleId><ArticleId IdType="pubmed">34312822</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, Abdo-Cuza A. Point-of-care ultrasound in the critically ill pregnant or postpartum patient: what every intensivist should know. Intensive Care Med 2019; 45: 1123&#x2013;6. https://doi.org/10.1007/s00134-019-05682-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05682-2</ArticleId><ArticleId IdType="pubmed">31270577</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 2020; 18: 2127&#x2013;33. https://doi.org/10.11124/jbisrir-d-19-00099</Citation></Reference><Reference><Citation>Erez O, Novack L, Beer-Weisel R, et al. DIC score in pregnant women--a population based modification of the International Society on Thrombosis and Hemostasis score. PloS One 2014; 9: e93240. https://doi.org/10.1371/journal.pone.0093240</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093240</ArticleId><ArticleId IdType="pubmed">24728139</ArticleId><ArticleId IdType="pmc">3984105</ArticleId></ArticleIdList></Reference><Reference><Citation>Barriuso V, Pombar X, Bankowski HA. The use of therapeutic hypothermia in the management of amniotic fluid embolism. Obstet Med 2013; 6: 92&#x2013;3. https://doi.org/10.1258/om.2011.110069</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/om.2011.110069</ArticleId><ArticleId IdType="pubmed">27757166</ArticleId><ArticleId IdType="pmc">5052767</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis E, Prota C, Matturro R, Citro R. Amniotic fluid embolism in a grown-up congenital heart disease patient. J Cardiovasc Echogr 2019; 29: 20&#x2013;2. https://doi.org/10.4103/jcecho.jcecho_64_18</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jcecho.jcecho_64_18</ArticleId><ArticleId IdType="pubmed">31008034</ArticleId><ArticleId IdType="pmc">6450229</ArticleId></ArticleIdList></Reference><Reference><Citation>Maack KH, Munk K, Dahl K, J&#xf8;rgensen HH, Christiansen A, Helmig RB. Right heart masses demonstrated by echocardiography in a patient with amniotic fluid embolism during labour. Acta Anaesthesiol Scand 2018; 62: 134&#x2013;7. https://doi.org/10.1111/aas.13006</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13006</ArticleId><ArticleId IdType="pubmed">28983905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein SN, Cudemus-Deseda GA, Ortiz VE, Goodman A, Jassar AS. Case 33-2019: a 35-year-old woman with cardiopulmonary arrest during cesarean section. N Engl J Med 2019; 381: 1664&#x2013;73. https://doi.org/10.1056/nejmcpc1904046</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmcpc1904046</ArticleId><ArticleId IdType="pubmed">31644848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi A, Knight DS, Augustine DX, et al. Echocardiographic assessment of the right heart in adults: a practical guideline from the British Society of Echocardiography. Echo Res Pract 2020; 7: G19&#x2013;41. https://doi.org/10.1530/erp-19-0051</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/erp-19-0051</ArticleId><ArticleId IdType="pubmed">32105053</ArticleId><ArticleId IdType="pmc">7077526</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandoli GE, Sciaccaluga C, Bandera F, et al. Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings. Heart Fail Rev 2021; 26: 263&#x2013;75. https://doi.org/10.1007/s10741-020-10014-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-020-10014-4</ArticleId><ArticleId IdType="pubmed">32860180</ArticleId></ArticleIdList></Reference><Reference><Citation>Viau-Lapointe J, Filewod N. Extracorporeal therapies for amniotic fluid embolism. Obstet Gynecol 2019; 134: 989&#x2013;94. https://doi.org/10.1097/aog.0000000000003513</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/aog.0000000000003513</ArticleId><ArticleId IdType="pubmed">31599831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabi M, Burstein BJ, Anavekar NS, Kashani KB, Jentzer JC. Associations of vasopressor requirements with echocardiographic parameters after out-of-hospital cardiac arrest. J Intensive Care Med 2022; 37: 518&#x2013;27. https://doi.org/10.1177/0885066621998936</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066621998936</ArticleId><ArticleId IdType="pubmed">34044666</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol 2009; 201: e1&#x2013;13. https://doi.org/10.1016/j.ajog.2009.04.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2009.04.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfw&#xe9;n L, Hildebrand K, Schierbeck S, et al. Focused cardiac ultrasound after return of spontaneous circulation in cardiac-arrest patients. Resuscitation 2019; 142: 16&#x2013;22. https://doi.org/10.1016/j.resuscitation.2019.06.282</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2019.06.282</ArticleId><ArticleId IdType="pubmed">31279947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zengin S, Yavuz E, Al B, et al. Benefits of cardiac sonography performed by a non-expert sonographer in patients with non-traumatic cardiopulmonary arrest. Resuscitation 2016; 102: 105&#x2013;9. https://doi.org/10.1016/j.resuscitation.2016.02.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2016.02.025</ArticleId><ArticleId IdType="pubmed">26956840</ArticleId></ArticleIdList></Reference><Reference><Citation>Balki M, Liu S, Le&#xf3;n JA, Baghirzada L. Epidemiology of cardiac arrest during hospitalization for delivery in canada: a nationwide study. Anesth Analg 2017; 124: 890&#x2013;7. https://doi.org/10.1213/ane.0000000000001877</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000001877</ArticleId><ArticleId IdType="pubmed">28151819</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill JO, Iqbal R, McGarry K. "Thrombus in transit"--the role of echocardiography in the diagnosis of massive pulmonary embolism and a review of the literature. Acta Cardiol 2002; 57: 291&#x2013;4. https://doi.org/10.2143/ac.57.4.2005429</Citation><ArticleIdList><ArticleId IdType="doi">10.2143/ac.57.4.2005429</ArticleId><ArticleId IdType="pubmed">12222699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen F, Wang L, Yang W, Chen Y. From appearance to essence: 10&#xa0;years review of atypical amniotic fluid embolism. Arch Gynecol Obstet 2016; 293: 329&#x2013;34. https://doi.org/10.1007/s00404-015-3785-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-015-3785-z</ArticleId><ArticleId IdType="pubmed">26092134</ArticleId></ArticleIdList></Reference><Reference><Citation>Albaroudi B, Haddad M, Albaroudi O, Abdel-Rahman ME, Jarman R, Harris T. Assessing left ventricular systolic function by emergency physician using point of care echocardiography compared to expert: systematic review and meta-analysis. Eur J Emerg Med 2022; 29: 18&#x2013;32. https://doi.org/10.1097/mej.0000000000000866</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mej.0000000000000866</ArticleId><ArticleId IdType="pubmed">34406134</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35549557</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal membrane oxygenation during pregnancy and peripartal. An international retrospective multicenter study.</ArticleTitle><Pagination><StartPage>966</StartPage><EndPage>972</EndPage><MedlinePgn>966-972</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/02676591221090668</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Extracorporeal Membrane Oxygenation (ECMO) may be used in the setting of pregnancy or the peripartal period, however its utility has not been well-characterized. This study aims to give an overview on the prevalence of peripartel ECMO cases and further assess the indications and outcomes of ECMO in this setting across multiple centers and countries.</AbstractText><AbstractText Label="METHODS">A retrospective, multicenter, international cohort study of pregnant and peripartum ECMO cases was performed. Data were collected from six ECMO centers across three continents over a 10-year period.</AbstractText><AbstractText Label="RESULTS">A total of 60 pregnany/peripartal ECMO cases have been identified. Most frequent indications are acute respiratory distress syndrome (<i>n</i> = 30) and pulmonary embolism (<i>n</i> = 5). Veno-venous ECMO mode was applied more often (77%). ECMO treatment during pregnancy was performed in 17 cases. Maternal and fetal survival was high with 87% (<i>n</i> = 52), respectively 73% (<i>n</i> = 44).</AbstractText><AbstractText Label="CONCLUSIONS">Various emergency scenarios during pregnancy and at time of delivery may require ECMO treatment. Peripartal mortality in a well-resourced setting is rare, however emergencies in the labor room occur and knowledge of available rescue therapy is essential to improve outcome. Obstetricians and obstetric anesthesiologists should be aware of the availability of ECMO resource at their hospital or region to ensure immediate contact when needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malfertheiner</LastName><ForeName>S Fill</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0002-4274-2526</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Hospital St. Hedwig of the Order of St. John, Regensburg University, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodie</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Acute Respiratory Failure, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burrell</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, The Alfred Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taccone</LastName><ForeName>F S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, H&#xf4;pital Erasme, Universit&#xe9; Libre de Bruxelles, ULB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broman</LastName><ForeName>L M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0003-4124-4581</Identifier><AffiliationInfo><Affiliation>ECMO Centre Karolinska, Department of Pediatric Perioperative Medicine and Intensive Care, Karolinska University Hospital, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shekar</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agerstrand</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Acute Respiratory Failure, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>A L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Acute Respiratory Failure, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malfertheiner</LastName><ForeName>M V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-6245-2614</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine II, Cardiology and Pneumology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">amniotic fluid embolism</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">hemorrhage</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">peripartum</Keyword><Keyword MajorTopicYN="N">pneumonia</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>13</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35549557</ArticleId><ArticleId IdType="pmc">PMC10265280</ArticleId><ArticleId IdType="doi">10.1177/02676591221090668</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brodie D, Slutsky AS, Combes A. Extracorporeal life support for adults with respiratory failure and related indications. JAMA 2019; 322: 557&#x2013;568. DOI: 10.1001/jama.2019.9302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.9302</ArticleId><ArticleId IdType="pubmed">31408142</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad SA, Broman LM, Taccone FS, et al.The extracorporeal life support organization maastricht treaty for nomenclature in extracorporeal life support. a position paper of the extracorporeal life support organization. Am J Respir Crit Care Med 2018; 198: 447&#x2013;451. DOI: 10.1164/rccm.201710-2130CP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201710-2130CP</ArticleId><ArticleId IdType="pmc">PMC6118026</ArticleId><ArticleId IdType="pubmed">29614239</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman LM, Taccone FS, Lorusso R, et al.The ELSO Maastricht Treaty for ECLS Nomenclature: abbreviations for cannulation configuration in extracorporeal life support - a position paper of the Extracorporeal Life Support Organization. Crit Care 2019; 23: 36. DOI: 10.1186/s13054-019-2334-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2334-8</ArticleId><ArticleId IdType="pmc">PMC6367794</ArticleId><ArticleId IdType="pubmed">30736845</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Brodie D, Strassmann S, et al.Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 2016; 42: 889&#x2013;896. DOI: 10.1007/s00134-016-4273-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4273-z</ArticleId><ArticleId IdType="pubmed">26942446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappalardo F, Montisci A. What is extracorporeal cardiopulmonary resuscitation? J Thorac Dis 2017; 9: 1415&#x2013;1419. DOI: 10.21037/jtd.2017.05.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2017.05.33</ArticleId><ArticleId IdType="pmc">PMC5506168</ArticleId><ArticleId IdType="pubmed">28740646</ArticleId></ArticleIdList></Reference><Reference><Citation>Patricio D, Peluso L, Brasseur A, et al.Comparison of extracorporeal and conventional cardiopulmonary resuscitation: a retrospective propensity score matched study. Crit Care 2019; 23: 27. DOI: 10.1186/s13054-019-2320-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2320-1</ArticleId><ArticleId IdType="pmc">PMC6348681</ArticleId><ArticleId IdType="pubmed">30691512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong J, Zhang JJY, Lorusso R, et al.Extracorporeal membrane oxygenation in pregnancy and the postpartum period: a systematic review of case reports. Int J Obstet Anesth 2020; 43: 106&#x2013;113. DOI: 10.1016/j.ijoa.2020.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijoa.2020.04.004</ArticleId><ArticleId IdType="pubmed">32439296</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore SA, Dietl CA, Coleman DM. Extracorporeal life support during pregnancy. J Thorac Cardiovasc Surg 2016; 151: 1154&#x2013;1160. DOI: 10.1016/j.jtcvs.2015.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2015.12.027</ArticleId><ArticleId IdType="pubmed">26825433</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen EE, Davis NL, Goodman D, et al.Vital signs: pregnancy-related deaths, United States, 2011-2015, and Strategies for Prevention, 13 States, 2013-2017. MMWR Morbidity Mortality Weekly Rep 2019; 68: 423&#x2013;429. DOI: 10.15585/mmwr.mm6818e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6818e1</ArticleId><ArticleId IdType="pmc">PMC6542194</ArticleId><ArticleId IdType="pubmed">31071074</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg CJ, Callaghan WM, Syverson C, et al.Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116: 1302&#x2013;1309. DOI: 10.1097/AOG.0b013e3181fdfb11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e3181fdfb11</ArticleId><ArticleId IdType="pubmed">21099595</ArticleId></ArticleIdList></Reference><Reference><Citation>Extracorporeal-life-support-organization . https://www.elso.org/resources/guidelines.aspx2020, (accessed 31.12.2020).</Citation></Reference><Reference><Citation>Dubar G., Azria E., Tesni&#xe8;re A, et al.French experience of 2009 A/H1N1v influenza in pregnant women. PLoS One 2010; 5: e13112. DOI: 10.1371/journal.pone.0013112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013112</ArticleId><ArticleId IdType="pmc">PMC2950136</ArticleId><ArticleId IdType="pubmed">20957195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma NS, Wille KM, Bellot SC, et al.Modern use of extracorporeal life support in pregnancy and postpartum. ASAIO J 2015; 61: 110&#x2013;114. DOI: 10.1097/MAT.0000000000000154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000154</ArticleId><ArticleId IdType="pubmed">25248040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankford AS, Chow JH, Jackson AM, et al.clinical outcomes of pregnant and postpartum extracorporeal membrane oxygenation patients. Anesth Analgesia 2021; 132: 777&#x2013;787. DOI: 10.1213/ANE.0000000000005266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000005266</ArticleId><ArticleId IdType="pubmed">33591093</ArticleId></ArticleIdList></Reference><Reference><Citation>Martillotti G, Boehlen F, Robert-Ebadi H, et al.Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review. J Thromb Haemost 2017; 15: 1942&#x2013;1950. DOI: 10.1111/jth.13802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13802</ArticleId><ArticleId IdType="pubmed">28805341</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen HP, Chang WC, Yeh LS, et al.Amniotic fluid embolism treated with emergency extracorporeal membrane oxygenation: a case report. J Reproductive Medicine 2009; 54: 706&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">20120905</ArticleId></ArticleIdList></Reference><Reference><Citation>Takacs ME, Damisch KE. Extracorporeal life support as salvage therapy for massive pulmonary embolus and cardiac arrest in pregnancy. J Emerg Med 2018; 55: 121&#x2013;124. DOI: 10.1016/j.jemermed.2018.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jemermed.2018.04.009</ArticleId><ArticleId IdType="pubmed">29739630</ArticleId></ArticleIdList></Reference><Reference><Citation>Depondt C, Arnaudovski D, Voulgaropoulos A, et al.Venoarterial extracorporeal membrane oxygenation as supportive therapy after cardiac arrest after amniotic fluid embolism: a case report. A&amp;A Pract 2019; 13: 74&#x2013;77. DOI: 10.1213/XAA.0000000000000995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/XAA.0000000000000995</ArticleId><ArticleId IdType="pubmed">30864952</ArticleId></ArticleIdList></Reference><Reference><Citation>Djordjevic I, Rahmanian P, Zeriouh M, et al.Treatment of cardiogenic shock in peripartum cardiomyopathy: Case series from a tertiary ECMO center, 35, 2019, pp. 254&#x2013;257. DOI: 10.1111/jocs.14324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14324</ArticleId><ArticleId IdType="pubmed">31705816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ull C, Schildhauer TA, Strauch JT, et al.Veno-venous ECMO as a safe bridge to recovery in a patient with severe peripartum cardiomyopathy - learning from errors. Perfusion 2017; 32: 328&#x2013;332. DOI: 10.1177/0267659116681436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659116681436</ArticleId><ArticleId IdType="pubmed">27881700</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-Y, Li Y-P, Lin S-Y, et al.Extracorporeal membrane oxygenation application in post-partum hemorrhage patients: Is post-partum hemorrhage contraindicated? J Obstet Gynaecol Res 2017; 43: 1649&#x2013;1654. DOI: 10.1111/jog.13426.2017/07/15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jog.13426</ArticleId><ArticleId IdType="pubmed">28707719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ried M, Bein T, Philipp A, et al.Extracorporeal lung support in trauma patients with severe chest injury and acute lung failure: a 10-year institutional experience. Crit Care (London, England) 2013; 17: R110. DOI: 10.1186/cc12782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc12782</ArticleId><ArticleId IdType="pmc">PMC4056791</ArticleId><ArticleId IdType="pubmed">23786965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M-Y, Chou P-L, Wu T-I, et al.Predictors of hospital mortality in adult trauma patients receiving extracorporeal membrane oxygenation for advanced life support: a retrospective cohort study. Scand J Trauma Resuscitation Emerg Med 2018; 26: 14&#x2013;26. DOI: 10.1186/s13049-018-0481-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-018-0481-6</ArticleId><ArticleId IdType="pmc">PMC5806237</ArticleId><ArticleId IdType="pubmed">29422067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJY, Ong JA-H, Syn NL, et al.Extracorporeal membrane oxygenation in pregnant and postpartum women: a systematic review and meta-regression analysis. J Intensive Care Med 2021; 36: 220&#x2013;228. DOI: 10.1177/0885066619892826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619892826</ArticleId><ArticleId IdType="pubmed">31829108</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Brodie D, Strassmann S, et al.Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 2016; 42: 889&#x2013;896. DOI: 10.1007/s00134-016-4273-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4273-z</ArticleId><ArticleId IdType="pubmed">26942446</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Schmidt M, Hodgson CL, et al.Extracorporeal life support for adults with acute respiratory distress syndrome. Intensive Care Med 2020; 46: 2464&#x2013;2476. DOI: 10.1007/s00134-020-06290-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06290-1</ArticleId><ArticleId IdType="pmc">PMC7605473</ArticleId><ArticleId IdType="pubmed">33140180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunz D., Calabr&#xf2; L., Belliato M, et al.Extracorporeal membrane oxygenation for refractory cardiac arrest: a retrospective multicenter study. Intensive Care Med 2020; 46: 973&#x2013;982. DOI: 10.1007/s00134-020-05926-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05926-6</ArticleId><ArticleId IdType="pubmed">32052069</ArticleId></ArticleIdList></Reference><Reference><Citation>Humberg A, H&#xe4;rtel C, Rausch TK, et al.Active perinatal care of preterm infants in the German Neonatal Network. Arch Dis Child - Fetal Neonatal Edition 2020; 105: 190&#x2013;195. DOI: 10.1136/archdischild-2018-316770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2018-316770</ArticleId><ArticleId IdType="pubmed">31248963</ArticleId></ArticleIdList></Reference><Reference><Citation>Malfertheiner MV, Philipp A, Lubnow M, et al.Hemostatic changes during extracorporeal membrane oxygenation. Crit Care Medicine 2016; 44: 747&#x2013;754. DOI: 10.1097/CCM.0000000000001482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001482</ArticleId><ArticleId IdType="pubmed">26646464</ArticleId></ArticleIdList></Reference><Reference><Citation>Malfertheiner MV, Pimenta LP, Bahr VV, et al.. Acquired von Willebrand syndrome in respiratory extracorporeal life support: a systematic review of the literature. Crit Care Resuscitation : Journal Australas Acad Crit Care Med 2017; 19: 45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">29084501</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CM, Smith KA, Manuck TA. Extracorporeal membrane oxygenation in pregnant and postpartum women: a ten-year case series. Am Journal Obstetrics Gynecology MFM 2020; 2: 100108. DOI: 10.1016/j.ajogmf.2020.100108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajogmf.2020.100108</ArticleId><ArticleId IdType="pmc">PMC7362433</ArticleId><ArticleId IdType="pubmed">32835205</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman LM, Dirnberger DR, Malfertheiner MV, et al.International survey on extracorporeal membrane oxygenation transport. ASAIO J 2020; 66: 214&#x2013;225. DOI: 10.1097/MAT.0000000000000997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000000997</ArticleId><ArticleId IdType="pubmed">30946060</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerstrand C, Abrams D, Biscotti M, et al.Extracorporeal membrane oxygenation for cardiopulmonary failure during pregnancy and postpartum. Ann Thorac Surg 2016; 102: 774&#x2013;779. DOI: 10.1016/j.athoracsur.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.03.005</ArticleId><ArticleId IdType="pubmed">27154158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38109996</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-9333</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>American journal of obstetrics &amp; gynecology MFM</Title><ISOAbbreviation>Am J Obstet Gynecol MFM</ISOAbbreviation></Journal><ArticleTitle>Use of cell salvage at the time of cesarean delivery: a meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>101257</StartPage><MedlinePgn>101257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajogmf.2023.101257</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2589-9333(23)00399-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Excess blood loss from obstetrical hemorrhage requires transfusion of donor blood, a finite resource. Intraoperative cell salvage collects a patient's own blood that has been lost during cesarean delivery and returns it to their own circulation. We performed a meta-analysis to examine the perioperative outcomes in patients receiving cell salvage at the time of cesarean delivery.</AbstractText><AbstractText Label="DATA SOURCES">Scopus, PubMed, Cochrane Central Register of Controlled Trials, Ovid Medline, and clinicaltrials.gov were searched from database inception through October 2023.</AbstractText><AbstractText Label="STUDY ELIGIBILITY CRITERIA">Eligible studies included randomized controlled trials comparing the use of cell salvage to standard-of-care during cesarean delivery.</AbstractText><AbstractText Label="METHODS">Two authors independently extracted data. Preferred Reporting Items of Systematic Reviews and Meta-Analysis guidelines were used for data extraction and quality assessment. The primary outcomes were the rate of donor blood transfusion and change in hemoglobin level. The secondary outcomes included transfusion reaction, amniotic fluid embolism, and length of hospital stay. Results were summarized as weighted mean difference or risk ratio with associated 95% confidence intervals. Heterogeneity was measured using Higgins I<sup>2</sup>.</AbstractText><AbstractText Label="RESULTS">A total of 5 randomized controlled trials (n=3361) comparing cell salvage to standard care during cesarean delivery met the inclusion criteria. Primary analysis showed a significant decrease in receiving allogeneic blood transfusion with intraoperative cell salvage use vs standard care (odds ratio, 0.32; 95% confidence interval, 0.23-0.46), with no change in hemoglobin drop (mean difference, -0.77; 95% confidence interval, -1.67 to -0.14). The secondary outcomes showed no difference in transfusion reaction (odds ratio, 0.56; 95% confidence interval, 0.06-5.59), and length of hospital stay (mean difference, -1.90; 95% confidence interval, -4.85 to 1.06). No cases of amniotic fluid embolism were reported among the 1685 patients who received cell salvage.</AbstractText><AbstractText Label="CONCLUSION">Use of cell salvage during cesarean delivery reduced the overall need for allogeneic blood transfusion without increasing the risk of complications, including no cases of amniotic fluid embolism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Neel S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA. Electronic address: neel.iyer@jefferson.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanuja</LastName><ForeName>Kavisha</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roman</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Kouatly</LastName><ForeName>Huda B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Obstet Gynecol MFM</MedlineTA><NlmUniqueID>101746609</NlmUniqueID><ISSNLinking>2589-9333</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="Y">Cesarean Section</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057725" MajorTopicYN="Y">Operative Blood Salvage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001804" MajorTopicYN="N">Blood Transfusion, Autologous</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006473" MajorTopicYN="N">Postpartum Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="N">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autologous transfusion</Keyword><Keyword MajorTopicYN="N">cell salvage</Keyword><Keyword MajorTopicYN="N">cesarean delivery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>13</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38109996</ArticleId><ArticleId IdType="doi">10.1016/j.ajogmf.2023.101257</ArticleId><ArticleId IdType="pii">S2589-9333(23)00399-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29166810</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4954</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The journal of maternal-fetal &amp; neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians</Title><ISOAbbreviation>J Matern Fetal Neonatal Med</ISOAbbreviation></Journal><ArticleTitle>Anesthetic management of amniotic fluid embolism -- a multi-center, retrospective, cohort study.</ArticleTitle><Pagination><StartPage>1262</StartPage><EndPage>1266</EndPage><MedlinePgn>1262-1266</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14767058.2017.1404024</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Amniotic fluid embolism (AFE) is a rare and potentially lethal obstetric complication, commonly occurring during labor, delivery, or immediately postpartum. There is a paucity of data regarding incidence, risk factors, and clinical management. Our primary objective in this study was to evaluate clinical presentation of AFE and delineate anesthesia management of these cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This 10 years retrospective multi-center cohort study was performed in five tertiary university-affiliated medical centers, between the years 2005 and 2015. All documented cases of AFE identified according to the ICD guidelines were reviewed manually to determine eligibility for AFE according to Clark's criteria. All cases confirming Clark's diagnosis were included in the cohort.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Throughout the study period, 20 cases of AFE were identified, with an incidence of 4.1 per 100,000 births. Average age at presentation was 35&#x2009;&#xb1;&#x2009;5 years. Seventy percent of cases presented during vaginal delivery, 20% occurred throughout a cesarean delivery, and 10% occurred during a dilation and evacuation procedure. The most common presenting symptom was sudden loss of consciousness in 12 parturients (66.7%), fetal bradycardia in 11 parturients (55%), and shortness of breath in 10 parturients (50%). Perimortem cesarean section was performed in 55% of cases, although only one case was performed in the delivery suite, while all others were performed in the operating room. Echocardiography was performed in 60% of the cases and all were pathological. Furthermore, 20% of cases were connected to an extracorporeal membrane oxygenation machine. There was a 15% mortality rate of 15%. A further 15% suffered major neurological disability, 25% suffered minor neurological morbidity, and 45% survived without severe complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AFE is associated with significant maternal morbidity. This study highlights the importance of providing advanced training for the delivery suite staff for cases of maternal cardiovascular collapse secondary to AFE and increasing awareness for this rare and devastating obstetric condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skolnik</LastName><ForeName>Shiri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Department of Anesthesia, and Sackler Faculty of Medicine , Rabin Medical Center, Beilinson Hospital, Petach Tikvah Israel, Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioscovich</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>b Department of Anesthesia , Shaare Zedek Medical Center, Hebrew University of Jerusalem , Jerusalem , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eidelman</LastName><ForeName>Leonid A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>a Department of Anesthesia, and Sackler Faculty of Medicine , Rabin Medical Center, Beilinson Hospital, Petach Tikvah Israel, Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Atara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Department of Anesthesia, and Sackler Faculty of Medicine , Rabin Medical Center, Beilinson Hospital, Petach Tikvah Israel, Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shmueli</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>c Department of Obstetrics and Gynecology, and Sackler Faculty of Medicine , Rabin Medical Center, Beilinson Hospital, Petach Tikvah Israel, Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aviram</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>d Lis Maternity and Women's Hospital, Tel Aviv Sourasky Medical Center , Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orbach-Zinger</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Department of Anesthesia, and Sackler Faculty of Medicine , Rabin Medical Center, Beilinson Hospital, Petach Tikvah Israel, Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Matern Fetal Neonatal Med</MedlineTA><NlmUniqueID>101136916</NlmUniqueID><ISSNLinking>1476-4954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Matern Fetal Neonatal Med. 2019 Sep;32(17):2953. doi: 10.1080/14767058.2017.1414742.</RefSource><PMID Version="1">29228841</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000773" MajorTopicYN="N">Anesthesia, Obstetrical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001919" MajorTopicYN="N">Bradycardia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036861" MajorTopicYN="N">Delivery, Obstetric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="N">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005315" MajorTopicYN="N">Fetal Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007743" MajorTopicYN="N">Labor, Obstetric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007744" MajorTopicYN="N">Obstetric Labor Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011249" MajorTopicYN="N">Pregnancy Complications, Cardiovascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014474" MajorTopicYN="N">Unconsciousness</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amniotic fluid</Keyword><Keyword MajorTopicYN="N">embolism</Keyword><Keyword MajorTopicYN="N">maternal morbidity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29166810</ArticleId><ArticleId IdType="doi">10.1080/14767058.2017.1404024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28282766</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4954</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The journal of maternal-fetal &amp; neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians</Title><ISOAbbreviation>J Matern Fetal Neonatal Med</ISOAbbreviation></Journal><ArticleTitle>Risk factors for fatality in amniotic fluid embolism: a systematic review and analysis of a data pool.</ArticleTitle><Pagination><StartPage>661</StartPage><EndPage>665</EndPage><MedlinePgn>661-665</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14767058.2017.1293034</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Investigating risk factors for amniotic fluid embolism (AFE)-induced fatality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review of cases of AFE available on PubMed, Scielo, Scopus and AJOL databases that occurred from 1990 to 2015 was carried out. After careful reading of titles, abstracts and full texts, case reports of AFE were reviewed. Risk factors for AFE were considered as independent variables in logistic regression models. The first model was built on the whole data pool. The second model was built on typical cases of AFE, according to the classical triad of symptoms (heart, lungs, coagulopathy). The dependent variable was fatality in both models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">177 cases of AFE were assessed in the first model, while 121 typical cases of AFE were assessed in the second model. Among typical cases of AFE, only oxytocin infusion during labour increases the likelihood of death (odds ratio 2.890, 95% confidence interval 1.166-7.164, p&#x2009;=&#x2009;0.022). No risk factors for fatality were found in the whole data pool.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Further research on national registries should focus on the behaviour of oxytocin infusion during labour in AFE cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Indraccolo</LastName><ForeName>Ugo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>a Complex Operative Unit of Obstetrics and Gynecology , "Alto Tevere" Hospital of Citt&#xe0; di Castello, ASL 1 Umbria , Citt&#xe0; di Castello , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battistoni</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>b Department of Gynecological, Obstetrical, and Urological Sciences , "Sapienza" University of Rome , Rome , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrantonio</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>b Department of Gynecological, Obstetrical, and Urological Sciences , "Sapienza" University of Rome , Rome , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Iorio</LastName><ForeName>Romolo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>c Department of Surgical and Clinical Sciences and Translational Medicine , "Sapienza" University of Rome , Rome , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Pantaleo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>d Department of Morphology, Surgery and Experimental Medicine , University of Ferrara , Ferrara , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Indraccolo</LastName><ForeName>Salvatore Renato</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>b Department of Gynecological, Obstetrical, and Urological Sciences , "Sapienza" University of Rome , Rome , Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Matern Fetal Neonatal Med</MedlineTA><NlmUniqueID>101136916</NlmUniqueID><ISSNLinking>1476-4954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="N">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amniotic fluid embolism</Keyword><Keyword MajorTopicYN="N">delivery</Keyword><Keyword MajorTopicYN="N">labour induction</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">oxytocin infusion</Keyword><Keyword MajorTopicYN="N">pregnancy complications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28282766</ArticleId><ArticleId IdType="doi">10.1080/14767058.2017.1293034</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39735018</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Risk Factors and Outcomes of Acute Pulmonary Embolism in African Patients: A Systematic Review.</ArticleTitle><Pagination><StartPage>e74673</StartPage><MedlinePgn>e74673</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e74673</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.74673</ELocationID><Abstract><AbstractText>Pulmonary embolism is a common cause of morbidity and mortality. Numerous risk factors have been identified that predispose patients to this disease. This study aims to identify these risk factors and the possible outcomes (recovery or mortality) after receiving treatment from any hospital. Healthcare is expensive in Africa, hence hindering its easy accessibility.&#xa0; PubMed, Scopus, and African Journals Online were searched from the database inception to October 2024 to identify relevant studies. A total of 719 articles were identified, for which 172 duplicate articles were removed. After screening 592 articles by title and abstract, 508 were excluded. Eighty-four articles were screened by full text to determine their eligibility. Finally, 13 articles were used in the final qualitative analysis. We included original research published in English in peer-reviewed journals from January 2000 to September 2024 that reported the risk factors and outcomes of pulmonary embolism, and studies that used computed tomography pulmonary angiography as a diagnosis of acute pulmonary embolism in patients more than 18 years old, irrespective of gender and medical or surgical condition, managed in any African hospital, were included. In total, 7650 patients were included in 13 articles, from 10 countries (Nigeria, Togo, Angola, Kenya, Cameroon, South Africa, Sierra Leone, Egypt, DR Congo, and Ethiopia), and 861 patients had pulmonary embolism. The mean age of the reported patients ranged from 40.8 to 64.4 years across the studies. There were 309 male and 552 female patients diagnosed with pulmonary embolism. The study types included in this review are retrospective studies,&#xa0;cross-sectional studies, and case-control studies. Deep vein thrombosis (DVT), heart disease, immobilization, obesity, smoking, recent surgery, and malignancy were the most commonly identified risk factors across the included articles. Pulmonary embolism contributes significantly to morbidity and mortality among African patients, with key risk factors including DVT, immobilization, heart disease, obesity, smoking, recent surgery, malignancy, pregnancy, and contraceptive use. Limited diagnostic resources in low-resource settings pose a major challenge, but adopting affordable diagnostic alternatives and clinical algorithms could improve outcomes by enabling earlier diagnosis and timely treatment. The availability and implementation of a standardized PE treatment protocol will ensure quality care, decrease mortality, and increase recovery rates.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Okeke et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okeke</LastName><ForeName>Collins C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadi</LastName><ForeName>Emmanuel S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hallel Hospital and Maternity, Port Harcourt, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebiliekwe</LastName><ForeName>Onyinye E</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekeocha</LastName><ForeName>Ifunanya R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nnanna Okoro</LastName><ForeName>Emeka</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Imo State University College of Medicine, Owerri, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nduji</LastName><ForeName>Oluchi J</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Abia State University, Uturu, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Undie</LastName><ForeName>Malipeh-Unim</ForeName><Initials>MU</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Surgery Interest Group of Africa, Lagos, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngige</LastName><ForeName>Onyinye</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eze-Odurukwe</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Salford Royal NHS Foundation Trust, Manchester, GBR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezema</LastName><ForeName>Chinecherem</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onyeogulu</LastName><ForeName>Afamefuna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojo</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Afe Babalola University, Ado Ekiti, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obuseh</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Delta State University Teaching Hospital, Oghara, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonta</LastName><ForeName>Kelechi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Unit, Department of Surgery, University of Port Harcourt Teaching Hospital, Port Harcourt, NGA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>30</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39735018</ArticleId><ArticleId IdType="pmc">PMC11681974</ArticleId><ArticleId IdType="doi">10.7759/cureus.74673</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pulmonary embolism. Tarbox AK, Swaroop M. Int J Crit Illn Inj Sci. 2013;3:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665123</ArticleId><ArticleId IdType="pubmed">23724389</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology, pathophysiology, and natural history of pulmonary embolism. Turetz M, Sideris AT, Friedman OA, Triphathi N, Horowitz JM. Semin Intervent Radiol. 2018;35:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986574</ArticleId><ArticleId IdType="pubmed">29872243</ArticleId></ArticleIdList></Reference><Reference><Citation>Global incidence and case fatality rate of pulmonary embolism following major surgery: a protocol for a systematic review and meta-analysis of cohort studies. Temgoua MN, Tochie JN, Noubiap JJ, Agbor VN, Danwang C, Endomba FT, Nkemngu NJ. Syst Rev. 2017;6:240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5716368</ArticleId><ArticleId IdType="pubmed">29202836</ArticleId></ArticleIdList></Reference><Reference><Citation>Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: vital registration data from 123&#xa0;countries. Barco S, Valerio L, Gallo A, et al. Res Pract Thromb Haemost. 2021;5:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268665</ArticleId><ArticleId IdType="pubmed">34263098</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AL. Pulmonary embolism symptoms and diagnosis.  [
Oct;
2024 
]. 2024. https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/symptoms-diagnosis https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/symptoms-diagnosis</Citation></Reference><Reference><Citation>Pulmonary embolism. Essien EO, Rali P, Mathai SC. Med Clin North Am. 2019;103:549&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">30955521</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary embolism (PE) clinical presentation. 2024. https://emedicine.medscape.com/article/300901-clinical https://emedicine.medscape.com/article/300901-clinical</Citation></Reference><Reference><Citation>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Page MJ, McKenzie JE, Bossuyt PM, et al. BMJ. 2021;372:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008539</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId></ArticleIdList></Reference><Reference><Citation>Critical appraisal tools.  [
Oct;
2024 
]. 2024. https://jbi.global/critical-appraisal-tools https://jbi.global/critical-appraisal-tools</Citation></Reference><Reference><Citation>Acute pulmonary thromboembolism: a retrospective study in a Nigerian private tertiary hospital. Ogunkoya J, Oluwole A, Adefuye B, Adebola-Yusuf AO, Ehioghae O. https://www.ajol.info/index.php/ahr/article/view/226821 Ann Health Res. 2021;7:107&#x2013;117.</Citation></Reference><Reference><Citation>Pulmonary embolism at the University Hospital Campus of Lome (Togo): a retrospective study about 51 cases [Article in French] Pessinaba S, Atti YD, Baragou S, et al. Pan Afr Med J. 2017;27:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567959</ArticleId><ArticleId IdType="pubmed">28904659</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical profile, management and outcomes of patients with pulmonary embolism: a retrospective tertiary centre study in Angola. Manuel A, Aufico A, Africano R, et al.  https://pubmed.ncbi.nlm.nih.gov/28556850/ Cardiovasc J Afr. 2017;28:356&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885046</ArticleId><ArticleId IdType="pubmed">28556850</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary thromboembolism in an East African tertiary referral hospital. Ogeng'o JA, Obimbo MM, Olabu BO, Gatonga PM, Ong'era D. J Thromb Thrombolysis. 2011;32:386&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">21674133</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute pulmonary embolism in the era of multi-detector CT: a reality in sub-Saharan Africa. Tambe J, Moifo B, Fongang E, Guegang E, Juimo AG. BMC Med Imaging. 2012;12:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485620</ArticleId><ArticleId IdType="pubmed">23072500</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical presentation and diagnostic work up of suspected pulmonary embolism in a district hospital emergency centre serving a high HIV/TB burden population. Bulajic B, Welzel T, Vallabh K. Afr J Emerg Med. 2019;9:134&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742596</ArticleId><ArticleId IdType="pubmed">31528531</ArticleId></ArticleIdList></Reference><Reference><Citation>The clinical features and management of pulmonary embolism at Chris Hani Baragwanath Academic Hospital. Meel S, Peter A, Menezes C. https://pmc.ncbi.nlm.nih.gov/articles/PMC8424778/ Afr J Thorac Crit Care Med. 2018;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8424778</ArticleId><ArticleId IdType="pubmed">34541509</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute pulmonary embolism in an intensive care unit setting in Sierra Leone. Russell JB, Baio S, Koroma TR, et al.  https://pubmed.ncbi.nlm.nih.gov/36260002/ West Afr J Med. 2022;39:997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">36260002</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient characteristics and predictors of pulmonary embolism in patients infected with COVID - 19 in Upper Egypt. Hussein A, Khalaf AM, Alsharawy LA, Abdelrazek G, Shafiq Awad M. Vasc Health Risk Manag. 2023;19:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10084826</ArticleId><ArticleId IdType="pubmed">37050930</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary embolism: epidemiological data and diagnosis in Kinshasa hospitals. Bakebe A, Kashongwe I, Mulenga C, et al. Int J Tuberc Lung Dis. 2017;21:875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">28786795</ArticleId></ArticleIdList></Reference><Reference><Citation>The value of electrocardiography in predicting inpatient mortality in patients with acute pulmonary embolism: a cross sectional analysis. Raghubeer N, Lahri S, Hendrikse C. Afr J Emerg Med. 2024;14:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10899042</ArticleId><ArticleId IdType="pubmed">38425642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hospital survival of patients with pulmonary embolism in a country with limited resources case of the city of Kinshasa. Marc TB, Michel TP, Florence M, et al. BMC Cardiovasc Disord. 2023;23:439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10476371</ArticleId><ArticleId IdType="pubmed">37667172</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and factors associated with pulmonary embolism among RT-PCR confirmed Covid-19 patients with upfront CT pulmonary angiography in Ethiopia: a nested casecontrol study. Belayneh EK, Leulseged TW, Tarekegn TK, et al.  https://www.ajol.info/index.php/emj/article/view/249901 Ethiop Med J. 2023;61:1.</Citation></Reference><Reference><Citation>Prevalence and risk factors of pulmonary embolism in COPD patients complicated with secondary polycythemia. Li J, Xiong Y, Li S, et al. Int J Chron Obstruct Pulmon Dis. 2024;19:2371&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11542496</ArticleId><ArticleId IdType="pubmed">39512997</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Arch Intern Med. 2000;160:809&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737280</ArticleId></ArticleIdList></Reference><Reference><Citation>A prospective study of risk factors for pulmonary embolism in women. Goldhaber SZ, Grodstein F, Stampfer MJ, et al.  https://pubmed.ncbi.nlm.nih.gov/9039882/ JAMA. 1997;277:642&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039882</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and risk factors for pulmonary embolism in the postpartum period. Morris JM, Algert CS, Roberts CL. J Thromb Haemost. 2010;8:998&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">20128859</ArticleId></ArticleIdList></Reference><Reference><Citation>Antenatal pulmonary embolism: risk factors, management and outcomes. Knight M. BJOG. 2008;115:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201281</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors for pulmonary embolism. The Framingham study. Goldhaber SZ, Savage DD, Garrison RJ, et al. Am J Med. 1983;74:1023&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859053</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factor and mortality in patients with pulmonary embolism combined with infectious disease. Lee GD, Ju S, Kim JY, et al. Tuberc Respir Dis (Seoul) 2020;83:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105430</ArticleId><ArticleId IdType="pubmed">32185917</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics, risk factors, and outcomes of acute pulmonary embolism in Asian population. Bumroongkit C, Deesomchok A, Liwsrisakun C, et al. J Clin Med. 2022;11:6954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741370</ArticleId><ArticleId IdType="pubmed">36498530</ArticleId></ArticleIdList></Reference><Reference><Citation>Outpatient treatment of pulmonary embolism with dalteparin. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. https://pubmed.ncbi.nlm.nih.gov/10739374/ Thromb Haemost. 2000;83:209&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">10739374</ArticleId></ArticleIdList></Reference><Reference><Citation>Catheter-directed thrombolysis compared with systemic thrombolysis and anticoagulation in patients with intermediate- or high-risk pulmonary embolism: systematic review and network meta-analysis. Planer D, Yanko S, Matok I, et al. CMAJ. 2023;195:0&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281204</ArticleId><ArticleId IdType="pubmed">37336568</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of interventions for intermediate to high-risk pulmonary embolism: a network meta-analysis. Ishisaka Y, Watanabe A, Fujisaki T, et al. Catheter Cardiovasc Interv. 2023;102:249&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">37269229</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of anticoagulation,&#xa0;catheter-directed thrombolysis, or systemic thrombolysis in acute&#xa0;pulmonary embolism. Zhang RS, Maqsood MH, Sharp AS, et al. JACC Cardiovasc Interv. 2023;16:2644&#x2013;2651.</Citation><ArticleIdList><ArticleId IdType="pubmed">37855802</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term mortality in patients with pulmonary embolism: results in a single-center registry. Eckelt J, Hobohm L, Merten MC, et al. Res Pract Thromb Haemost. 2023;7:100280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10439384</ArticleId><ArticleId IdType="pubmed">37601025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculosis and venous thromboembolism: a case series. Goncalves IM, Alves DC, Carvalho A, do Ceu Brito M, Calvario F, Duarte R. Cases J. 2009;2:9333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804722</ArticleId><ArticleId IdType="pubmed">20066058</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence of venous thromboembolism in tuberculosis patients. Ambrosetti M, Ferrarese M, Codecasa LR, Besozzi G, Sarassi A, Viggiani P, Migliori GB. Respiration. 2006;73:396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16439829</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculose (TB)  [
Nov;
2024 
]. 2024. https://www.afro.who.int/health-topics/tuberculosis-tb https://www.afro.who.int/health-topics/tuberculosis-tb</Citation></Reference><Reference><Citation>HIV/AIDS.  [
Nov;
2024 
]. 2024. https://www.afro.who.int/health-topics/hivaids https://www.afro.who.int/health-topics/hivaids</Citation></Reference><Reference><Citation>Acute pulmonary embolism in patients with HIV disease. Howling SJ, Shaw PJ, Miller RF. Sex Transm Infect. 1999;75:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1758180</ArticleId><ArticleId IdType="pubmed">10448338</ArticleId></ArticleIdList></Reference><Reference><Citation>Venous thromboembolic disease in the HIV-infected patient. Malek J, Rogers R, Kufera J, Hirshon JM. Am J Emerg Med. 2011;29:278&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">20825798</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS and thrombosis: retrospective study of 131 HIV-infected patients. Saif MW, Bona R, Greenberg B. AIDS Patient Care STDS. 2001;15:311&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16946213</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0029-7844</ISSN><JournalIssue CitedMedium="Print"><Volume>108</Volume><Issue>3 Pt 1</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Obstetrics and gynecology</Title><ISOAbbreviation>Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Postpartum maternal mortality and cesarean delivery.</ArticleTitle><Pagination><StartPage>541</StartPage><EndPage>548</EndPage><MedlinePgn>541-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A continuous rise in the rate of cesarean delivery has been reported in many countries during the past decades. This trend has prompted the emergence of a controversial debate on the risks and benefits associated with cesarean delivery. Our objective was to provide a valid estimate of the risk of postpartum maternal death directly associated with cesarean as compared with vaginal delivery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A population-based case-control study was designed, with subjects selected from recent nationwide surveys in France. To control for indication bias, maternal deaths due to antenatal morbidities were excluded. For the 5-year study period 1996-2000, 65 cases were included. The control group was selected from the 1998 French National Perinatal Survey and included 10,244 women. Multivariable logistic regression analysis was used to adjust for confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjustment for potential confounders, the risk of postpartum death was 3.6 times higher after cesarean than after vaginal delivery (odds ratio 3.64 95% confidence interval 2.15-6.19). Both prepartum and intrapartum cesarean delivery were associated with a significantly increased risk. Cesarean delivery was associated with a significantly increased risk of maternal death from complications of anesthesia, puerperal infection, and venous thromboembolism. The risk of death from postpartum hemorrhage did not differ significantly between vaginal and cesarean deliveries.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cesarean delivery is associated with an increased risk of postpartum maternal death. Knowledge of the causes of death associated with this excess risk informs contemporary discussion about cesarean delivery on request and should inform preventive strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deneux-Tharaux</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, Unite Mixte de Recherche S149, Institut Federatif de Recherche 69, Epidemiological Research Unit on Perinatal and Women's Health, Hopital Tenon, Paris, France. cdeneux.u149@chusa.jussieu.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona</LastName><ForeName>Elodie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bouvier-Colle</LastName><ForeName>Marie-H&#xe9;lene</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Br&#xe9;art</LastName><ForeName>G&#xe9;rard</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obstet Gynecol</MedlineTA><NlmUniqueID>0401101</NlmUniqueID><ISSNLinking>0029-7844</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036861" MajorTopicYN="N">Delivery, Obstetric</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="N">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005865" MajorTopicYN="N">Gestational Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006771" MajorTopicYN="N">Hospitals, Maternity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008428" MajorTopicYN="Y">Maternal Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010298" MajorTopicYN="N">Parity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006473" MajorTopicYN="N">Postpartum Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16946213</ArticleId><ArticleId IdType="doi">10.1097/01.AOG.0000233154.62729.24</ArticleId><ArticleId IdType="pii">108/3/541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33719164</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1447-0756</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of obstetrics and gynaecology research</Title><ISOAbbreviation>J Obstet Gynaecol Res</ISOAbbreviation></Journal><ArticleTitle>Biochemical effects of intraoperative cell salvage and autotransfusion during cesarean section: A prospective pilot study.</ArticleTitle><Pagination><StartPage>1743</StartPage><EndPage>1750</EndPage><MedlinePgn>1743-1750</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jog.14738</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Intraoperative cell salvage and autotransfusion (ICSA) is a useful technique for women undergoing cesarean sections who are predicted to experience significant bleeding. This method can reduce allogeneic transfusions as well as its associated risks and costs. Amniotic fluid embolism (AFE) is an abnormal maternal response to ICSA similar to the classic systemic inflammatory response syndrome, but its mechanism is not well understood. This study was conducted to investigate the biochemical aspects of AFE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective case-controlled pilot study was conducted in a general perinatal hospital in Japan. ICSA was performed using a two-step retransfusion process. Blood samples were collected presurgery, immediately postsurgery, and 24&#x2009;h after surgery. Changes in sialyl Tn antigen (STN), complement C3 and C4, fibrinogen, and fibrin degradation product and D-dimer, C1 esterase inhibitor, and interleukin-8 (all considered AFE-related markers) activities were compared between patients who underwent cesarean sections with ICSA (ICSA group) versus without ICSA (control group).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fibrinogen levels were significantly lower in the ICSA group than in the control group before surgery but not immediately after or 24&#x2009;h after surgery. D-dimer was significantly higher immediately after surgery but not 24&#x2009;h later. STN was significantly lower only before surgery. None of the AFE-related markers showed significant differences between the groups after 24&#x2009;h. No adverse events were observed in the ICSA group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is no clinical evidence that ICSA alters the biochemical statuses of AFE-related markers in a manner that could lead to adverse maternal responses.</AbstractText><CopyrightInformation>&#xa9; 2021 Japan Society of Obstetrics and Gynecology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayata</LastName><ForeName>Eijiro</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8555-3007</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakata</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3621-1251</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagasaki</LastName><ForeName>Sumito</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oji</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakuma</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morita</LastName><ForeName>Mineto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Toho University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Obstet Gynaecol Res</MedlineTA><NlmUniqueID>9612761</NlmUniqueID><ISSNLinking>1341-8076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001804" MajorTopicYN="N">Blood Transfusion, Autologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="Y">Cesarean Section</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="Y">Embolism, Amniotic Fluid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amniotic fluid embolism</Keyword><Keyword MajorTopicYN="N">autotransfusion</Keyword><Keyword MajorTopicYN="N">biochemical marker</Keyword><Keyword MajorTopicYN="N">disseminated intravascular coagulation</Keyword><Keyword MajorTopicYN="N">intraoperative cell salvage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>15</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33719164</ArticleId><ArticleId IdType="doi">10.1111/jog.14738</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Dhariwal SK, Khan KS, Allard S, Wilson M, Moore P, SALVO study group. Does current evidence support the use of intraoperative cell salvage in reducing the need for blood transfusion in caesarean section. Curr Opin Obstet Gynecol. 2014;26:425-30.</Citation></Reference><Reference><Citation>Morikawa M, Kuramoto A, Nakayama M, Oguchi H, Hasegawa M, Funakoshi T, et al. Intraoperative red cell salvage during obstetric surgery in 50 Japanese women. Int J Gynaecol Obstet. 2015;128:256-9.</Citation></Reference><Reference><Citation>Khan KS, Moore PAS, Wilson MJ, Hooper R, Allard S, Wrench I, et al. Cell salvage and donor blood transfusion during cesarean section: a pragmatic, multicentre randomised controlled trial (SALVO). PLoS Med. 2017;14:e1002471.</Citation></Reference><Reference><Citation>Sullivan IJ, Ralph CJ. Obstetric intra-operative cell salvage: a review of an established cell salvage service with 1170 re-infused cases. Anaesthesia. 2019;74:976-83.</Citation></Reference><Reference><Citation>Albright CM, Rouse DJ, Werner EF. Cost savings of red cell salvage during cesarean delivery. Obstet Gynecol. 2014;124:690-6.</Citation></Reference><Reference><Citation>Clark SL, Pavlova Z, Greenspoon J, Horenstein J, Phelan JP. Squamous cells in the maternal pulmonary circulation. Am J Obstet Gynecol. 1986;154:104-6.</Citation></Reference><Reference><Citation>Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2014;123:337-48.</Citation></Reference><Reference><Citation>Clark SL, Romero R, Dildy GA, Callaghan WM, Smiley RM, Bracey AW, et al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 2016;215:408-12.</Citation></Reference><Reference><Citation>Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. Med Hypotheses. 2007;68:1019-25.</Citation></Reference><Reference><Citation>Kanayama N, Tamura N. Amniotic fluid embolism: pathophysiology and new strategies for management. J Obstet Gynaecol Res. 2014;40:1507-17.</Citation></Reference><Reference><Citation>Tamura N, Kimura S, Farhana M, Uchida T, Suzuki K, Sugihara K, et al. C1 esterase inhibitor activity in amniotic fluid embolism. Crit Care Med. 2014;42:1392-6.</Citation></Reference><Reference><Citation>McDonnell NJ, Kennedy D, Long LJ, Gallagher-Swann MC, Paech MJ. The development and implementation of an obstetric cell salvage service. Anaesth Intensive Care. 2010;38:492-9.</Citation></Reference><Reference><Citation>Waters JH, Biscotti C, Potter PS, Phillipson E. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000;92:1531-6.</Citation></Reference><Reference><Citation>Fong J, Gurewitsch ED, Kump L, Klein R. Clearance of fetal products and subsequent immunoreactivity of blood salvaged at cesarean delivery. Obstet Gynecol. 1999;93:968-72.</Citation></Reference><Reference><Citation>Sullivan I, Faulds J, Ralph C. Contamination of salvaged maternal blood by amniotic fluid and fetal red cells during elective caesarean section. Br J Anaesth. 2008;101:225-9.</Citation></Reference><Reference><Citation>Keeling MM, Gray LA, Brink MA, Hillerich VK, Bland KI. Intraoperative autotransfusion. Experience in 725 consecutive cases. Ann Surg. 1983;197:536-41.</Citation></Reference><Reference><Citation>Zichella L, Gramolini R. Autotransfusion during cesarean section. Am J Obstet Gynecol. 1990;162:295.</Citation></Reference><Reference><Citation>Okunuga A, Skelton VA. Use of cell salvage in patients with sickle cell trait. Int J Obstet Anesth. 2009;18:90-1. author reply 91.</Citation></Reference><Reference><Citation>Allam J, Cox M, Yentis SM. Cell salvage in obstetrics. Int J Obstet Anesth. 2008;17:37-45.</Citation></Reference><Reference><Citation>Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172:1158-67. discussion 1167-1169.</Citation></Reference><Reference><Citation>Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201(445):e1-13.</Citation></Reference><Reference><Citation>Courtney LD. Amniotic fluid embolism. Obstet Gynecol Surv. 1974;29:169-77.</Citation></Reference><Reference><Citation>Benson MD, Kobayashi H, Silver RK, Oi H, Greenberger PA, Terao T. Immunologic studies in presumed amniotic fluid embolism. Obstet Gynecol. 2001;97:510-4.</Citation></Reference><Reference><Citation>Waters JH, Tuohy MJ, Hobson DF, Procop G. Bacterial reduction by cell salvage washing and leukocyte depletion filtration. Anesthesiology. 2003;99:652-5.</Citation></Reference><Reference><Citation>Kanayama N, Yamazaki T, Naruse H, Sumimoto K, Horiuchi K, Terao T. Determining zinc coproporphyrin in maternal plasma-a new method for diagnosing amniotic fluid embolism. Clin Chem. 1992;38:526-9.</Citation></Reference><Reference><Citation>Legrand M, Rossignol M, Dreux S, Luton D, Ventr&#xe9; C, Barranger E, et al. Diagnostic accuracy of insulin-like growth factor binding protein-1 for amniotic fluid embolism*. Crit Care Med. 2012;40:2059-63.</Citation></Reference><Reference><Citation>Sreelakshmi TR, Eldridge J. Acute hypotension associated with leucocyte depletion filters during cell salvaged blood transfusion. Anaesthesia. 2010;65:742-4.</Citation></Reference><Reference><Citation>Waldron S. Hypotension associated with leucocyte depletion filters following cell salvage in obstetrics. Anaesthesia. 2011;66:133-4.</Citation></Reference><Reference><Citation>Ram&#xed;rez G, Romero A, Garc&#xed;a-Vallejo JJ, Mu&#xf1;oz M. Detection and removal of fat particles from postoperative salvaged blood in orthopedic surgery. Transfusion. 2002;42:66-75.</Citation></Reference><Reference><Citation>Bernstein HH, Rosenblatt MA, Gettes M, Lockwood C. The ability of the Haemonetics 4 cell saver system to remove tissue factor from blood contaminated with amniotic fluid. Anesth Analg. 1997;85:831-3.</Citation></Reference><Reference><Citation>Weiskopf RB. Erythrocyte salvage during cesarean section. Anesthesiology. 2000;92:1519-22.</Citation></Reference><Reference><Citation>Catling S, Joels L. Cell salvage in obstetrics: the time has come. BJOG. 2005;112:131-2.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17055946</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>368</Volume><Issue>9545</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study.</ArticleTitle><Pagination><StartPage>1444</StartPage><EndPage>1448</EndPage><MedlinePgn>1444-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amniotic-fluid embolism is a rare, but serious and often fatal maternal complication of delivery, of which the cause is unknown. We undertook an epidemiological study to investigate the association between amniotic-fluid embolism and medical induction of labour.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a population-based cohort of 3 million hospital deliveries in Canada between 1991 and 2002 to assess the associations between overall and fatal rates of amniotic-fluid embolism and medical and surgical induction, maternal age, fetal presentation, mode of delivery, and pregnancy and labour complications.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Total rate of amniotic-fluid embolism was 14.8 per 100,000 multiple-birth deliveries and 6.0 per 100,000 singleton deliveries (odds ratio 2.5 [95% CI 0.9-6.2]). Of the 180 cases of amniotic-fluid embolism in women with singleton deliveries during the study period, 24 (13%) were fatal. We saw no significant temporal increase in occurrence of amniotic-fluid embolism for total or fatal cases. Medical induction of labour nearly doubled the risk of overall cases of amniotic-fluid embolism (adjusted odds ratio 1.8 [1.3-2.7]), and the association was stronger for fatal cases (crude odds ratio 3.5 [1.5-8.4]). Maternal age of 35 years or older, caesarean or instrumental vaginal delivery, polyhydramnios, cervical laceration or uterine rupture, placenta previa or abruption, eclampsia, and fetal distress were also associated with an increased risk.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Medical induction of labour seems to increase the risk of amniotic-fluid embolism. Although the absolute excess risk is low, women and physicians should be aware of this risk when making decisions about elective labour induction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Department of Epidemiology and Biostatistics, McGill University Faculty of Medicine, Montreal, QC, Canada. michael.kramer@mcgill.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Baskett</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><CollectiveName>Maternal Health Study Group of the Canadian Perinatal Surveillance System</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2006 Oct 21;368(9545):1399-401. doi: 10.1016/S0140-6736(06)69581-0.</RefSource><PMID Version="1">17055926</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="Y">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007751" MajorTopicYN="Y">Labor, Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008423" MajorTopicYN="N">Maternal Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17055946</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(06)69607-4</ArticleId><ArticleId IdType="pii">S0140-6736(06)69607-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40152587</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2163-0763</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The journal of trauma and acute care surgery</Title><ISOAbbreviation>J Trauma Acute Care Surg</ISOAbbreviation></Journal><ArticleTitle>Ketamine infusion for pain control in severely injured patients: Results of a randomized controlled trial.</ArticleTitle><Pagination><StartPage>858</StartPage><EndPage>866</EndPage><MedlinePgn>858-866</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0000000000004602</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Opiate-based pain regimens remain the cornerstone of pain management following traumatic injury, but issues related to opioids have driven research into alternative analgesics. Adjunctive ketamine has been increasingly used to decrease opioid use, but little evidence exists to support its efficacy within the trauma population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, randomized, double-blind placebo-controlled trial of severely injured (Injury Severity Score [ISS], &#x2265;15) adult patients (aged 18-64 years) admitted to a Level 1 trauma center was conducted. Exclusion criteria included Glasgow Coma Scale score of &lt;14, ISS of &lt;15, pregnancy, and chronic opiate use. All patients were prescribed a patient-controlled analgesia in addition to being randomized to either adjustable dose ketamine starting at 3 &#x3bc;g/kg/min or an equivalent rate of 0.9% normal saline. Study drug and patient-controlled analgesia titration were allowed as part of a treatment algorithm. The primary outcome was reduction in oral morphine equivalent (OME) utilization at 24 hours.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We performed a planned interim analysis upon reaching a predetermined enrollment goal. Forty-two of 78 patients (53.8%) were randomized to the experimental arm. Both groups were similar in makeup and had a median ISS of 22 (19, 28.5). The median OMEs in adjustable dose ketamine and placebo groups were 110.6 (55.7, 191.7) and 99.2 (50.6, 172.6), respectively ( p = 0.85). No significant difference in OME was found in 24- to 48-hour or the entire 48-hour study period. Adjustable dose ketamine had no impact on pain scores throughout the study period when compared with placebo (4.9 vs. 4.7, p = 0.95). These findings met the futility cutoff, and enrollment was terminated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adjustable dose ketamine failed to reduce OME totals or pain scores in a severely injured trauma cohort when compared with placebo at any time point. Additional studies are necessary to determine if there is any benefit for adjuvant ketamine in different trauma subpopulations.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Therapeutic/Care Management; Level I.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American Association for the Surgery of Trauma.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carver</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0001-9904-2152</Identifier><AffiliationInfo><Affiliation>From the Division of Trauma and Critical Care Surgery, Department of Surgery (T.W.C., W.J.P., J.A.G., C.T., M.M.-W., J.R.P., M.E.S., D.J.M., A.F.E., M.A.d.M., T.A.d.R-C.), Division of Regional Anesthesia and Acute Pain Management (R.T.), and Division of Biostatistics, Institute for Health &amp; Equity (A.S., Y.Y.), Medical College of Wisconsin, Milwaukee, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peppard</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Gellings</LastName><ForeName>Jaclyn A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Thapa</LastName><ForeName>Rozalin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Trevino</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mantz-Wichman</LastName><ForeName>Margo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Peschman</LastName><ForeName>Jacob R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Aniko</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yushan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Milia</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Elegbede</LastName><ForeName>Anuoluwapo F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>de Moya</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>de Roon-Cassini</LastName><ForeName>Terri A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT no. 042</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma Acute Care Surg</MedlineTA><NlmUniqueID>101570622</NlmUniqueID><ISSNLinking>2163-0755</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016058" MajorTopicYN="N">Analgesia, Patient-Controlled</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="Y">Analgesics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="Y">Pain</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="Y">Pain Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="Y">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ketamine</Keyword><Keyword MajorTopicYN="N">opioids</Keyword><Keyword MajorTopicYN="N">pain management</Keyword><Keyword MajorTopicYN="N">severe injury</Keyword><Keyword MajorTopicYN="N">trauma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40152587</ArticleId><ArticleId IdType="doi">10.1097/TA.0000000000004602</ArticleId><ArticleId IdType="pii">01586154-202506000-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gross JL, Perate AR, Elkassabany NM. Pain management in trauma in the age of the opioid crisis. Anesthesiol Clin . 2019;37:79&#x2013;91.</Citation></Reference><Reference><Citation>Alghnam S, Castillo R. Traumatic injuries and persistent opioid use in the USA: findings from a nationally representative survey. Inj Prev . 2017;23:87&#x2013;92.</Citation></Reference><Reference><Citation>Harvin JA, Truong VTT, Green CE, Allen L, Murry J, Radosevich JJ, et al. Opioid exposure after injury in United States trauma centers: a prospective, multicenter observational study. J Trauma Acute Care Surg . 2020;88:816&#x2013;824.</Citation></Reference><Reference><Citation>Cote C, Berube M, Moore L, Lauzier F, Tremblay L, Belzile E, et al. Strategies aimed at preventing long-term opioid use in trauma and orthopaedic surgery: a scoping review. BMC Musculoskelet Disord . 2022;23:238.</Citation></Reference><Reference><Citation>Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med . 2010;11:1859&#x2013;1871.</Citation></Reference><Reference><Citation>deRoon-Cassini TA, Hunt JC, Geier TJ, Warren AM, Ruggiero KJ, Scott K, et al. Screening and treating hospitalized trauma survivors for posttraumatic stress disorder and depression. J Trauma Acute Care Surg . 2019;87:440&#x2013;450.</Citation></Reference><Reference><Citation>Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg . 2004;99:482&#x2013;495.</Citation></Reference><Reference><Citation>Lui F, Ng KF. Adjuvant analgesics in acute pain. Expert Opin Pharmacother . 2011;12:363&#x2013;385.</Citation></Reference><Reference><Citation>Ahern TL, Herring AA, Anderson ES, Madia VA, Fahimi J, Frazee BW. The first 500: initial experience with widespread use of low-dose ketamine for acute pain management in the ED. Am J Emerg Med . 2015;33:197&#x2013;201.</Citation></Reference><Reference><Citation>Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med . 2018;43:456&#x2013;466.</Citation></Reference><Reference><Citation>Sleigh J, Harvey M, Voss L, Denny B. Ketamine &#x2014; more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care . 2014;4:76&#x2013;81.</Citation></Reference><Reference><Citation>Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet . 2016;55:1059&#x2013;1077.</Citation></Reference><Reference><Citation>Barrett W, Buxhoeveden M, Dhillon S. Ketamine: a versatile tool for anesthesia and analgesia. Curr Opin Anaesthesiol . 2020;33:633&#x2013;638.</Citation></Reference><Reference><Citation>Bell RF, Dahl JB, Moore RA, Kalso E. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand . 2005;49:1405&#x2013;1428.</Citation></Reference><Reference><Citation>Zakine J, Samarcq D, Lorne E, Moubarak M, Montravers P, Beloucif S, et al. Postoperative ketamine administration decreases morphine consumption in major abdominal surgery: a prospective, randomized, double-blind, controlled study. Anesth Analg . 2008;106:1856&#x2013;1861.</Citation></Reference><Reference><Citation>Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth . 2011;58:911&#x2013;923.</Citation></Reference><Reference><Citation>Losing AK, Jones JM, Keric A, Briggs SE, Leedahl DD. Ketamine infusion therapy as an alternative pain control strategy in patients with multi-trauma including rib fracture; case report and literature review. Bull Emerg Trauma . 2016;4:165&#x2013;169.</Citation></Reference><Reference><Citation>Pruskowski KA, Harbourt K, Pajoumand M, Chui SJ, Reynolds HN. Impact of ketamine use on adjunctive analgesic and sedative medications in critically ill trauma patients. Pharmacotherapy . 2017;37:1537&#x2013;1544.</Citation></Reference><Reference><Citation>Walters MK, Farhat J, Bischoff J, Foss M, Evans C. Ketamine as an analgesic adjuvant in adult trauma intensive care unit patients with rib fracture. Ann Pharmacother . 2018;52:849&#x2013;854.</Citation></Reference><Reference><Citation>Mullins CF, Kugler NW, Luc M, Peppard WJ, Paul JS. Adjunct ketamine infusions provide improved acute traumatic and post-surgical pain management. J Pharmacol Med Chem . 2018;2:36&#x2013;38.</Citation></Reference><Reference><Citation>Takieddine SC, Droege CA, Ernst N, Droege ME, Webb M, Branson RD, et al. Ketamine versus hydromorphone patient-controlled analgesia for acute pain in trauma patients. J Surg Res . 2018;225:6&#x2013;14.</Citation></Reference><Reference><Citation>Peppard W, Carver T. Ketamine for the management of acute pain and agitation in the ICU: future, fiction or just another drug-induced hallucination? Ann Pharmacol Pharm . 2017;2:1059.</Citation></Reference><Reference><Citation>Kugler NW, Carver TW, Juul J, Peppard WJ, Boyle K, Drescher KM, et al. Ketamine infusion for pain control in elderly patients with multiple rib fractures: results of a randomized controlled trial. J Trauma Acute Care Surg . 2019;87:1181&#x2013;1188.</Citation></Reference><Reference><Citation>Carver TW, Kugler NW, Juul J, Peppard WJ, Drescher KM, Somberg LB, et al. Ketamine infusion for pain control in adult patients with multiple rib fractures: results of a randomized control trial. J Trauma Acute Care Surg . 2019;86:181&#x2013;188.</Citation></Reference><Reference><Citation>Klugh JM, Puzio TJ, Wandling MW, Guy-Frank CJ, Green C, Sergot PB, et al. Ketamine for acute pain after trauma (KAPT): a pragmatic, randomized clinical trial. J Trauma Acute Care Surg . 2024;97:514&#x2013;519.</Citation></Reference><Reference><Citation>Nordness MF, Hayhurst CJ, Pandharipande P. Current perspectives on the assessment and management of pain in the intensive care unit. J Pain Res . 2021;14:1733&#x2013;1744.</Citation></Reference><Reference><Citation>DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med . 1994;13:1341&#x2013;1352 discussion 1353&#x2013;6.</Citation></Reference><Reference><Citation>Hwang I, Shih W, De Cani J. Group sequential designs using a family of type I error probability spending functions. Stat Med . 1990;9:1439&#x2013;1445.</Citation></Reference><Reference><Citation>Jouguelet-Lacoste J, La Colla L, Schilling D, Chelly JE. The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med . 2015;16:383&#x2013;403.</Citation></Reference><Reference><Citation>Spilman SK, Lechtenberg GT, Hahn KD, Fuchsen EA, Olson SD, Swegle JR, et al. Is pain really undertreated? Challenges of addressing pain in trauma patients during prehospital transport and trauma resuscitation. Injury . 2016;47:2018&#x2013;2024.</Citation></Reference><Reference><Citation>Karmakar MK, Ho AM. Acute pain management of patients with multiple fractured ribs. J Trauma . 2003;54:615&#x2013;625.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39704317</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Cell salvage for the management of postpartum haemorrhage.</ArticleTitle><Pagination><StartPage>CD016120</StartPage><MedlinePgn>CD016120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD016120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD016120</ELocationID><Abstract><AbstractText Label="RATIONALE">Postpartum haemorrhage (PPH), defined as a blood loss of 500 mL or more within 24 hours of birth, is the leading global cause of maternal morbidity and mortality. Allogenic blood transfusions are a critical component of PPH management, yet are often unfeasible, particularly in resource-poor settings where maternal morbidity is highest. Autologous cell salvage in the management of PPH has been proposed to combat limitations in access to allogenic blood and potential transfusion-related risks. This review examines the benefits and harms of using cell salvage for pregnant women during birth.</AbstractText><AbstractText Label="OBJECTIVES">To assess the benefits and harms of cell salvage when used during birth.</AbstractText><AbstractText Label="SEARCH METHODS">We searched the CENTRAL, MEDLINE, Ovid Embase, and Global Index Medicus databases and the ICTRP and ClinicalTrials.gov trials registers. We also carried out reference checking and citation searching, and contacted study authors to identify all relevant studies. The latest search date was 8 February 2024.</AbstractText><AbstractText Label="ELIGIBILITY CRITERIA">We included randomised controlled trials (RCTs) in pregnant women (24 weeks or more gestation) comparing use of cell salvage following caesarean or vaginal birth with routine care (defined as no cell salvage). We did not place any restrictions on mode of birth, ethnicity, race, socioeconomic status, education level, or place of residence.</AbstractText><AbstractText Label="OUTCOMES">Critical outcomes for this review were risk of allogenic blood transfusion, risk of transfusion-related adverse reactions, risk of haemorrhage, transfer to higher level of care, length of hospitalisation, length of operation, and risk of sepsis. Important outcomes were estimated blood loss, blood loss &#x2265; 500 mL, blood loss &#x2265; 1000 mL, use of additional uterotonics or tranexamic acid, maternal death, postpartum haemoglobin concentration, change in haemoglobin, major surgery including hysterectomy, future major surgery, end-organ dysfunction or failure, amniotic fluid embolism, side effects, clotting abnormalities, maternal experience/satisfaction, maternal well-being, and breastfeeding.</AbstractText><AbstractText Label="RISK OF BIAS">We assessed risk of bias using the Cochrane risk of bias tool (RoB 1) for each critical outcome from each RCT.</AbstractText><AbstractText Label="SYNTHESIS METHODS">We conducted a meta-analysis for each outcome where data were available from more than one study using a random-effects model. If data could not be analysed using meta-analysis, we synthesised results narratively using the Synthesis Without Meta-analysis (SWiM) guidance. We used GRADE to assess the certainty of evidence for each outcome.</AbstractText><AbstractText Label="INCLUDED STUDIES">We included six RCTs with 3476 participants. All trials involved pregnant women having a caesarean birth. Three trials were conducted in high-income countries, and three were conducted in an upper-middle-income country.</AbstractText><AbstractText Label="SYNTHESIS OF RESULTS">Allogenic blood transfusion Intraoperative cell salvage at caesarean birth may reduce the need for allogenic transfusions received by participants, although the 95% confidence interval (CI) includes the possibility of an increase in effect. Low-certainty evidence from three studies found the risk of donor transfusions was possibly lower in participants with cell salvage (risk ratio (RR) 0.45, 95% CI 0.15 to 1.33; P = 0.15, I<sup>2</sup> = 33%; 3 RCTs, 3115 women; low-certainty evidence). The absolute risk of transfusion was very low in the studies (4% in women not treated with cell salvage and 2% in women treated with cell salvage). Transfusion-related adverse reactions The evidence is very uncertain about the risk of transfusion-related adverse reactions in participants with intraoperative cell salvage (RR 0.48, 95% CI 0.09 to 2.62; P = 0.39; 4 RCTs, 3304 women; very low-certainty evidence). Haemorrhage Two studies reported risk of haemorrhage and found that there was probably no difference between arms (RR 0.88, 95% CI 0.67 to 1.15; P = 0.36, I&#xb2; = 0%; 2 RCTs, 3077 women; moderate-certainty evidence). Length of hospitalisation The evidence is very uncertain about whether interoperative cell salvage at caesarean birth affects length of hospitalisation. Three studies reported length of hospitalisation (MD -2.02 days, 95% CI -4.73 to 0.70; P = 0.15, I<sup>2</sup> = 100%; 3 RCTs, 3174 women; very low-certainty evidence). Length of operation Two studies reported on length of operation. However, meta-analysis was not possible due to statistical heterogeneity and divergence of study findings; the direction of effect could not be determined. We evaluated the evidence as very low certainty. Sepsis One study reported risk of sepsis, finding that there was possibly no difference between arms (RR 1.00, 95% CI 0.43 to 2.29; P = 0.99; 1 RCT, 2990 women; low-certainty evidence). Estimated blood loss Cell salvage at caesarean birth may reduce blood loss. Two studies reported that estimated blood loss was possibly lower in women who had cell salvage compared to those who did not (MD -113.59 mL, 95% CI -130.41 to -96.77; P &lt; 0.00001, I<sup>2</sup> = 0%; 2 RCTs, 246 women; low-certainty evidence). Postpartum haemoglobin concentration Cell salvage at caesarean birth may increase day one postpartum haemoglobin. Three studies reported day one postpartum haemoglobin levels (MD 6.14 g/L, 95% CI 1.62 to 10.65; P = 0.008, I<sup>2</sup> = 97%; 3 RCTs, 3070 women; low-certainty evidence). Amniotic fluid embolism Three trials reported risk of amniotic fluid embolism and no cases were observed (n = 3226 women).</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">Cell salvage may reduce the need for allogenic blood transfusion, may reduce blood loss, and may increase day one postpartum haemoglobin in pregnant women having caesarean birth (low certainty). Cell salvage may make little to no difference to the risk of sepsis (low certainty) and probably makes little to no difference to the risk of haemorrhage (moderate certainty). The effect of cell salvage on risk of transfusion-related adverse reactions is very uncertain. The effect of cell salvage on the length of hospital stay was both clinically and statistically heterogenous, with a very low certainty of evidence. The effect of cell salvage on length of operation is divergent and meta-analysis was not possible due to significant statistical heterogeneity; the evidence is of very low certainty. No cases of amniotic fluid embolism were reported among the included trials. Studies in low- and middle-income settings are needed.</AbstractText><AbstractText Label="FUNDING">This review had no dedicated funding.</AbstractText><AbstractText Label="REGISTRATION">This review was registered with PROSPERO (CRD42024554204).</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Teesta</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Maia G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Ruaraidh A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Liverpool Reviews and Implementation Group, Department of Health Data Science, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaplin</LastName><ForeName>Marty</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huffstetler</LastName><ForeName>Hanna E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Health Behaviour, UNC Gillings School of Global Public Health, Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Ffion</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Liverpool Reviews and Implementation Group, Department of Health Data Science, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006473" MajorTopicYN="Y">Postpartum Hemorrhage</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001804" MajorTopicYN="N">Blood Transfusion, Autologous</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057725" MajorTopicYN="N">Operative Blood Salvage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036861" MajorTopicYN="N">Delivery, Obstetric</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Teesta Dey declares no conflicts of interest. Daisy Brown declares no conflicts of interest. Maia Cole declares no conflicts of interest. Ruaraidh Hill declares a financial, non&#x2010;personal, non&#x2010;specific interest, having delivered educational workshops on health economics, medicines management, and HTA for cancer specialists supported by unrestricted sponsorship by the pharmaceutical industry and an industry association (Bristol Myers Squibb Company, March 2019). No fees received personally. Marty Chaplin is an Editor for Cochrane Infectious Diseases, but had no involvement in the editorial processing of this review. Hanna Huffstetler is a technical consultant supporting the evidence assessments for the upcoming WHO recommendations related to the joint consolidated guidelines on the prevention, detection, and treatment of postpartum haemorrhage. Ffion Curtis declares no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39704317</ArticleId><ArticleId IdType="pmc">PMC11660225</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD016120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division. Trends in maternal mortality 2000 to 2020: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division. WHO, 2023.</Citation></Reference><Reference><Citation>WHO. WHO recommendations for the prevention and treatment of postpartum haemorrhage. WHO, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">23586122</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey T, Weeks AD. Identification, prevention and management of post-partum haemorrhage. Obstetrics, Gynaecology &amp; Reproductive Medicine 2020;30(8):231-41.</Citation></Reference><Reference><Citation>Carroll C, Young F. Intraoperative cell salvage. BJA Education 2021;21(3):95e101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892352</ArticleId><ArticleId IdType="pubmed">33664978</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. Intraoperative blood cell salvage in obstetrics: Interventional procedures guidance [IPG144]. www.nice.org.uk/guidance/ipg144 2005.</Citation></Reference><Reference><Citation>Lloyd TD, Geneen LJ, Bernhardt K, McClune W, Fernquest SJ, Brown T, et al. Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery. Cochrane Database of Systematic Reviews 2023, Issue 9. Art. No: CD001888. [DOI: 10.1002/14651858.CD001888.pub5]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001888.pub5</ArticleId><ArticleId IdType="pmc">PMC10486190</ArticleId><ArticleId IdType="pubmed">37681564</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan KS, Moore P, Wilson M, Hooper R, Allard S, Wrench I, et al. A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the salvo (cell salvage in obstetrics) trial. Health Technology Assessment (Winchester, England) 2018;22(2):1-88. [DOI: 10.3310/hta22020]</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta22020</ArticleId><ArticleId IdType="pmc">PMC5776407</ArticleId><ArticleId IdType="pubmed">29318985</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Lasserson T, Thomas J, Flemyng E, Churchill R. Methodological Expectations of Cochrane Intervention Reviews, Version August 2023. London: Cochrane, 2023.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Meher S, Cuthbert A, Kirkham JJ, Williamson P, Abalos E, Aflaifel N, et al. Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. British Journal of Obstetrics and Gynaecology 2019;126:83-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">29920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated October 2023). Cochrane, 2023. Available from training.cochrane.org/handbook.</Citation></Reference><Reference><Citation>Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 10 January 2024. Available at https://www.covidence.org.</Citation></Reference><Reference><Citation>Weeks J, Cuthbert A, Alfirevic Z. Trustworthiness assessment as an inclusion criterion for systematic reviews&#x2014;What is the impact on results? Cochrane Evidence Synthesis and Methods 2023;1(10):e12037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11795932</ArticleId><ArticleId IdType="pubmed">40476011</ArticleId></ArticleIdList></Reference><Reference><Citation>Review Manager (RevMan). Version 7.12.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.</Citation></Reference><Reference><Citation>Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.</Citation></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology 2014;14:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Akter S, Forbes G, Vazquez Corona M, Miller S, Althabe F, Coomarasamy A, et al. Perceptions and experiences of the prevention, detection, and management of postpartum haemorrhage: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews 2023, Issue 11. Art. No: CD013795. [DOI: 10.1002/14651858.CD013795.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013795.pub2</ArticleId><ArticleId IdType="pmc">PMC10680124</ArticleId><ArticleId IdType="pubmed">38009552</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann H, Bro&#x17c;ek J, Guyatt G, Oxman A. GRADE Handbook. GRADE, 2013.</Citation></Reference><Reference><Citation>Cell Salvage During Caesarean Section (CSCS). https://clinicaltrials.gov/study/NCT03429790#participation-criteria.</Citation></Reference><Reference><Citation>Geoghegan J, Middleton L, Moore P, Subseson G, Khan K, Daniels J. Routine cell salvage during elective caesarean section: a pilot randomised trial. International Journal of Obstetric Anesthesia 2015;24(1):86-7. [DOI: 10.1016/j.ijoa.2014.08.003]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijoa.2014.08.003</ArticleId><ArticleId IdType="pubmed">25499013</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr T, Wrench I. Trends in the use of intraoperative cell salvage in a tertiary obstetric centre over eight years. International Journal of Obstetric Anesthesia 2018;35(Suppl 1):S21.</Citation></Reference><Reference><Citation>Khan KS, Moore PAS, Wilson MJ, Hooper R, Allard S, Wrench I, et al; SALVO study group. Cell salvage and donor blood transfusion during cesarean section: a pragmatic, multicentre randomised controlled trial (SALVO). PLOS Medicine 2017;4(12):e1002471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736174</ArticleId><ArticleId IdType="pubmed">29261655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei B, Guo M, Deng X, He S, Lu X, Wang Y, et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage-evidence from a prospective randomized controlled trial. Frontiers in Immunology 2022;13:953334. [DOI: 10.3389/fimmu.2022.953334]</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.953334</ArticleId><ArticleId IdType="pmc">PMC9589269</ArticleId><ArticleId IdType="pubmed">36300123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Li X, Che X, Zhao G, Xu M. Intraoperative cell salvage for obstetrics: a prospective randomized controlled clinical trial. BMC Pregnancy and Childbirth 2020;20(1):452. [DOI: 10.1186/s12884-020-03138-w]</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12884-020-03138-w</ArticleId><ArticleId IdType="pmc">PMC7412832</ArticleId><ArticleId IdType="pubmed">32767971</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainaldi MP, Tazzari PL, Scagliarini G, Borghi B, Conte R. Blood salvage during caesarean section. British Journal of Anaesthesia 1998;80(2):195-8. [DOI: 10.1093/bja/80.2.195]</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/80.2.195</ArticleId><ArticleId IdType="pubmed">9602584</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y-F, Cao Y-D. Effect of intraoperative cell rescue on bleeding related indexes after cesarean section. World Journal of Clinical Cases 2022;10(8):2439-46. [DOI: 10.12998/wjcc.v10.i8.2439]</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i8.2439</ArticleId><ArticleId IdType="pmc">PMC8968603</ArticleId><ArticleId IdType="pubmed">35434071</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeson C, Jones M, Odendaal J, Choksey F, Quenby S. Routine use of cell salvage during cesarean section: a practice evaluation. Acta Obstetricia et Gynecologica Scandinavica 2024;103:498-504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10867391</ArticleId><ArticleId IdType="pubmed">38117692</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer NS, Khanuja K, Roman A, Al-Kouatly HB. Use of cell salvage at the time of cesarean delivery: a meta-analysis of randomized controlled trials. American Journal of Obstetrics &amp; Gynecology MFM 2024;6(2):101257.</Citation><ArticleIdList><ArticleId IdType="pubmed">38109996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G, Melnyk V, Facco FL, Waters JH, Smith KJ. Cost-effectiveness analysis of intraoperative cell salvage for obstetric hemorrhage. Anesthesiology 2018;128(2):328-37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771819</ArticleId><ArticleId IdType="pubmed">29194062</ArticleId></ArticleIdList></Reference><Reference><Citation>Obore N; Liuxiao Z; Haomin Y; Yuchen T; Wang L; Hong Y. Intraoperative Cell Salvage for Women at High Risk of Postpartum Hemorrhage During Cesarean Section: a Systematic Review and Meta-analysis. Reproductive sciences 2022;29(11):3161-3176.</Citation><ArticleIdList><ArticleId IdType="pubmed">35023053</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell OM, Cegolon L, Macleod D, Benova L. Length of stay after childbirth in 92 countries and associated factors in 30 low- and middle-income countries: compilation of reported data and a cross-sectional analysis from nationally representative surveys. PLOS Medicine 2016;13(3):e1001972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4783077</ArticleId><ArticleId IdType="pubmed">26954561</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwy Al-Beity F, Pembe AB, Kwezi HA, Massawe SN, Hanson C, Baker U. &#x201c;We do what we can do to save a woman&#x201d; health workers&#x2019; perceptions of health facility readiness for management of postpartum haemorrhage. Global Health Action 2020;13(1):1707403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7006654</ArticleId><ArticleId IdType="pubmed">31928163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G, Kotsis E, Zorn JM, Dalby PL, Ralph CJ, Waters JH. Cell salvage for postpartum haemorrhage during vaginal delivery: a case series.. Blood Transfusion 2018;16(6):498-501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214826</ArticleId><ArticleId IdType="pubmed">29106356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29528468</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-8785</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>American journal of perinatology</Title><ISOAbbreviation>Am J Perinatol</ISOAbbreviation></Journal><ArticleTitle>A Prediction Model for Severe Maternal Morbidity in Laboring Patients at Term.</ArticleTitle><Pagination><StartPage>8</StartPage><EndPage>14</EndPage><MedlinePgn>8-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0038-1626716</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the factors associated with severe maternal morbidity in a modern cohort of women laboring at term and to create a prediction model.</AbstractText><AbstractText Label="STUDY DESIGN">This is a retrospective cohort study of all term, laboring patients with live births at a single tertiary care center from 2004 to 2014. The primary outcome was composite maternal morbidity including organ failure, amniotic fluid embolism, anesthesia complications, sepsis, shock, thrombotic events, transfusion, or hysterectomy. Multivariable logistic regression was used to identify independent risk factors. Antepartum, intrapartum, and combined risk scores were created and test characteristics were analyzed.</AbstractText><AbstractText Label="RESULTS">Among 19,249 women delivering during the study period, 323 (1.68%) patients experienced severe morbidity, with blood transfusion the most common complication (286, 1.49%). Factors in the antepartum model included advanced maternal age, race, hypertension, nulliparity, history of cesarean delivery, smoking, and unfavorable Bishop score. Intrapartum factors included mode of delivery, use of cervical ripening agents or oxytocin, prolonged second stage, and macrosomia. The combined model had an area under the curve of 0.76 (95% confidence interval [CI], 0.73, 0.79).</AbstractText><AbstractText Label="CONCLUSION">This three-part risk scoring system can help clinicians counsel patients and guide clinical decision making for anticipating severe maternal morbidity and necessary resources.</AbstractText><CopyrightInformation>Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>Joshua I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuuli</LastName><ForeName>Methodius G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stout</LastName><ForeName>Molly J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Omar M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolfolk</LastName><ForeName>Candice L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Julia D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macones</LastName><ForeName>George A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Alison G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Perinatol</MedlineTA><NlmUniqueID>8405212</NlmUniqueID><ISSNLinking>0735-1631</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="N">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036861" MajorTopicYN="Y">Delivery, Obstetric</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013513" MajorTopicYN="Y">Obstetric Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="Y">Pregnancy Complications</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047929" MajorTopicYN="Y">Term Birth</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29528468</ArticleId><ArticleId IdType="doi">10.1055/s-0038-1626716</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21720243</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1175</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Anesthesiology</Title><ISOAbbreviation>Anesthesiology</ISOAbbreviation></Journal><ArticleTitle>Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports.</ArticleTitle><Pagination><StartPage>1201</StartPage><EndPage>1208</EndPage><MedlinePgn>1201-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/ALN.0b013e31821bdcfd</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with amniotic fluid embolism (AFE) (major cardiac and pulmonary symptoms plus consumptive coagulopathy) have high circulating tissue factor concentrations. Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue factor and form intravascular clots. A systematic review was done of case reports from 2003 to 2009 of AFE patients with massive hemorrhage who were and were not treated with rVIIa to assess the thrombotic complication risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE was searched for case reports of AFE patients receiving rVIIa (rVIIa cases) and of AFE patients who received surgery to control bleeding but no rVIIa (cohorts who did not receive rVIIa). Additional AFE case reports were obtained from the Food and Drug Administration, the Australian and New Zealand Haemostasis Registry, and scientific meeting abstracts. The risk of a negative outcome (permanent disability or death) in rVIIa cases versus cohorts who did not receive rVIIa was calculated using risk ratio and 95% confidence interval.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixteen rVIIa cases and 28 cohorts were identified who did not receive rVIIa. All patients had surgery to control bleeding. Death, permanent disability, and full recovery occurred in 8, 6, and 2 rVIIa cases and 7, 4, and 17 cohorts who did not receive rVIIa (risk ratio 2.2, 95% CI 1.4-3.7 for death or permanent disability vs. full recovery).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Recombinant factor VIIa cases had significantly worse outcomes than cohorts who did not receive rVIIa. It is recommended that rVIIa be used in AFE patients only when the hemorrhage cannot be stopped by massive blood component replacement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leighton</LastName><ForeName>Barbara L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Washington University in Saint Louis School of Medicine, St. Louis, Missouri 63110, USA. leightob@wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Lockhart</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Louise E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Zatta</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesthesiology</MedlineTA><NlmUniqueID>1300217</NlmUniqueID><ISSNLinking>0003-3022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003029">Coagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>AC71R787OV</RegistryNumber><NameOfSubstance UI="C103587">recombinant FVIIa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.21</RegistryNumber><NameOfSubstance UI="D015942">Factor VIIa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Anesthesiology. 2012 Aug;117(2):423; author reply 423-4. doi: 10.1097/ALN.0b013e31825b6c77.</RefSource><PMID Version="1">22828419</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003029" MajorTopicYN="N">Coagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="N">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015942" MajorTopicYN="N">Factor VIIa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N">New Zealand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21720243</ArticleId><ArticleId IdType="doi">10.1097/ALN.0b013e31821bdcfd</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29261655</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Cell salvage and donor blood transfusion during cesarean section: A pragmatic, multicentre randomised controlled trial (SALVO).</ArticleTitle><Pagination><StartPage>e1002471</StartPage><MedlinePgn>e1002471</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002471</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002471</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Excessive haemorrhage at cesarean section requires donor (allogeneic) blood transfusion. Cell salvage may reduce this requirement.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We conducted a pragmatic randomised controlled trial (at 26 obstetric units; participants recruited from 4 June 2013 to 17 April 2016) of routine cell salvage use (intervention) versus current standard of care without routine salvage use (control) in cesarean section among women at risk of haemorrhage. Randomisation was stratified, using random permuted blocks of variable sizes. In an intention-to-treat analysis, we used multivariable models, adjusting for stratification variables and prognostic factors identified a priori, to compare rates of donor blood transfusion (primary outcome) and fetomaternal haemorrhage &#x2265;2 ml in RhD-negative women with RhD-positive babies (a secondary outcome) between groups. Among 3,028 women randomised (2,990 analysed), 95.6% of 1,498 assigned to intervention had cell salvage deployed (50.8% had salvaged blood returned; mean 259.9 ml) versus 3.9% of 1,492 assigned to control. Donor blood transfusion rate was 3.5% in the control group versus 2.5% in the intervention group (adjusted odds ratio [OR] 0.65, 95% confidence interval [CI] 0.42 to 1.01, p = 0.056; adjusted risk difference -1.03, 95% CI -2.13 to 0.06). In a planned subgroup analysis, the transfusion rate was 4.6% in women assigned to control versus 3.0% in the intervention group among emergency cesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 2.2% versus 1.8% among elective cesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83) (interaction p = 0.46). No case of amniotic fluid embolism was observed. The rate of fetomaternal haemorrhage was higher with the intervention (10.5% in the control group versus 25.6% in the intervention group, adjusted OR 5.63, 95% CI 1.43 to 22.14, p = 0.013). We are unable to comment on long-term antibody sensitisation effects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The overall reduction observed in donor blood transfusion associated with the routine use of cell salvage during cesarean section was not statistically significant.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This trial was prospectively registered on ISRCTN as trial number 66118656 and can be viewed on http://www.isrctn.com/ISRCTN66118656.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Khalid S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Women's Health Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Philip A S</ForeName><Initials>PAS</Initials><Identifier Source="ORCID">0000-0001-7048-1493</Identifier><AffiliationInfo><Affiliation>Birmingham Women's Hospital, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>School of Health and Related Research, University of Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary University of London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allard</LastName><ForeName>Shubha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHS Blood and Transplant, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrench</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beresford</LastName><ForeName>Lee</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7754-8053</Identifier><AffiliationInfo><Affiliation>Pragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary University of London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Tracy E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0002-0624-0537</Identifier><AffiliationInfo><Affiliation>Health Economics Unit, Institute of Applied Health Research, University of Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLoughlin</LastName><ForeName>Carol</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6861-8259</Identifier><AffiliationInfo><Affiliation>Health Economics Unit, Institute of Applied Health Research, University of Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geoghegan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Birmingham Women's Hospital, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>Jane P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-3324-6771</Identifier><AffiliationInfo><Affiliation>Nottingham Clinical Trials Unit, University of Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catling</LastName><ForeName>Sue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Singleton Hospital, Swansea, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Vicki A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayuk</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robson</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Cellular Medicine, Newcastle University, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao-Smith</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Peri-operative, Critical Care and Trauma Trials Group, University of Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogg</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanz</LastName><ForeName>Doris</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9879-3069</Identifier><AffiliationInfo><Affiliation>Women's Health Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodds</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Women's Health Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SALVO study group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>10/57/32</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Anaesthesia. 2018 Dec;73(12):1574-1575. doi: 10.1111/anae.14464.</RefSource><PMID Version="1">30412294</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001782" MajorTopicYN="N">Blood Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001804" MajorTopicYN="N">Blood Transfusion, Autologous</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="Y">Cesarean Section</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057725" MajorTopicYN="N">Operative Blood Salvage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal&#x2019;s policy and the authors of this manuscript have the following competing interests: Primary NIHR grant supporting the roles of KK, PM, RH, IW, LB, TR, CM, JDa, SR, DL and JDo. PM also declares having been a co-applicant for two other NIHR-funded grants over within the last five years. Other than this, all authors declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29261655</ArticleId><ArticleId IdType="pmc">PMC5736174</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002471</ArticleId><ArticleId IdType="pii">PMEDICINE-D-17-02640</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Betran AP, Torloni MR, Zhang JJ, G&#xfc;lmezoglu AM, WHO Working Group on Caesarean Section. WHO statement on caesarean section rates. BJOG. 2016;123(5):667&#x2013;70. doi: 10.1111/1471-0528.13526
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.13526</ArticleId><ArticleId IdType="pmc">PMC5034743</ArticleId><ArticleId IdType="pubmed">26681211</ArticleId></ArticleIdList></Reference><Reference><Citation>Centre for Maternal and Child Enquiries. Saving mothers lives: reviewing maternal deaths to make motherhood safer: 2006&#x2013;2008. BJOG. 2011;118(Suppl 1):1&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">21356004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodelon C, Bernabe-Ortiz A, Schiff MA, Reed SD. Factors associated with peripartum hysterectomy. Obstet Gynecol. 2009;114(1):115&#x2013;23. doi: 10.1097/AOG.0b013e3181a81cdd
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e3181a81cdd</ArticleId><ArticleId IdType="pmc">PMC2714706</ArticleId><ArticleId IdType="pubmed">19546767</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care National Audit &amp; Research Centre. Female admissions (aged 16&#x2013;50 years) to adult, general critical care units in England, Wales and Northern Ireland reported as &#x2018;currently pregnant&#x2019; or &#x2018;recently pregnant&#x2019;. London: Obstetric Anaesthetists&#x2019; Association; 2013.</Citation></Reference><Reference><Citation>Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg. 2010;110(5):1368&#x2013;73. doi: 10.1213/ANE.0b013e3181d74898
</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e3181d74898</ArticleId><ArticleId IdType="pubmed">20237047</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Blood and Transplant. Saving and improving lives: strategic plan 2015&#x2013;20. London: NHS Blood and Transplant; 2015.</Citation></Reference><Reference><Citation>Catling S. Intraoperative cell salvage in obstetrics. Clin Risk. 2008;14(1):14&#x2013;7.</Citation></Reference><Reference><Citation>Shander A, Isbister J, Gombotz H. Patient blood management: the global view. Transfusion. 2016;56(Suppl 1):S94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">27001367</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, et al. 
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. Transfusion. 2015;55(12):2807&#x2013;15. doi: 10.1111/trf.13260
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.13260</ArticleId><ArticleId IdType="pubmed">26264557</ArticleId></ArticleIdList></Reference><Reference><Citation>Woman Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105&#x2013;16. doi: 10.1016/S0140-6736(17)30638-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30638-4</ArticleId><ArticleId IdType="pmc">PMC5446563</ArticleId><ArticleId IdType="pubmed">28456509</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardine JE, Law P, Hogg M, Murphy D, Khan KS, C-SAFETY. Haemorrhage at caesarean section: a framework for prevention and research. Curr Opin Obstet Gynecol. 2016;28(6):492&#x2013;8. doi: 10.1097/GCO.0000000000000328
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GCO.0000000000000328</ArticleId><ArticleId IdType="pubmed">27787286</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess. 2006;10(44):1&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">17049141</ArticleId></ArticleIdList></Reference><Reference><Citation>Carless PA, Henry DA, Moxey AJ, O&#x2019;Connell D, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010;2010(3):CD001888.</Citation></Reference><Reference><Citation>White J, Qureshi H, Massey E, Needs M, Byrne G, Daniels G, et al. 
Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med. 2016;26(4):246&#x2013;63. doi: 10.1111/tme.12299
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tme.12299</ArticleId><ArticleId IdType="pubmed">27074872</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, et al. British Committee for Standards in Haematology guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014;24(1):8&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25121158</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhariwal SK, Khan KS, Allard S, Wilson M, Moore P, SALVO study group. Does current evidence support the use of intraoperative cell salvage in reducing the need for blood transfusion in caesarean section?
Curr Opin Obstet Gynecol. 2014;26(6):425&#x2013;30. doi: 10.1097/GCO.0000000000000116
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GCO.0000000000000116</ArticleId><ArticleId IdType="pmc">PMC4338583</ArticleId><ArticleId IdType="pubmed">25259949</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoghegan J, Middleton L, Moore P, Subseson G, Khan K, Daniels J. Routine cell salvage during elective caesarean section: a pilot randomised trial. Int J Obstet Anesth. 2015;24(1):86&#x2013;7. doi: 10.1016/j.ijoa.2014.08.003
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijoa.2014.08.003</ArticleId><ArticleId IdType="pubmed">25499013</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoghegan J, Daniels JP, Moore PA, Thompson PJ, Khan KS, G&#xfc;lmezoglu AM. Cell salvage at caesarean section: the need for an evidence-based approach. BJOG. 2009;116(6):743&#x2013;7. doi: 10.1111/j.1471-0528.2009.02129.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-0528.2009.02129.x</ArticleId><ArticleId IdType="pubmed">19432562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainaldi MP, Tazzari PL, Scagliarini G, Borghi B, Conte R. Blood salvage during caesarean section. Br J Anaesth. 1998;80(2):195&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9602584</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebarber A, Lonser R, Jackson S, Copel JA, Sipes S. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol. 1998;179(3 Pt 1):715&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9757977</ArticleId></ArticleIdList></Reference><Reference><Citation>Royal College of Obstetricians and Gynaecologists, Royal College of Anaesthetists. Classification of urgency of caesarean section&#x2014;a continuum of risk. Good Practice No. 11. London: Royal College of Obstetricians and Gynaecologists; 2010.</Citation></Reference><Reference><Citation>Lucas DN, Yentis SM, Kinsella SM, Holdcroft A, May AE, Wee M, et al. 
Urgency of caesarean section: a new classification. J R Soc Med. 2000;93(7):346&#x2013;50. doi: 10.1177/014107680009300703
</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014107680009300703</ArticleId><ArticleId IdType="pmc">PMC1298057</ArticleId><ArticleId IdType="pubmed">10928020</ArticleId></ArticleIdList></Reference><Reference><Citation>Royal College of Obstetricians and Gynaecologists. Placenta praevia, placenta praevia accreta and vasa praevia: diagnosis and management. Green-top Guideline No. 27. London: Royal College of Obstetricians and Gynaecologists; 2011.</Citation></Reference><Reference><Citation>Haynes SL, Bennett JR, Torella F, McCollum CN. Does washing swabs increase the efficiency of red cell recovery by cell salvage in aortic surgery?
Vox Sang. 2005;88(4):244&#x2013;8. doi: 10.1111/j.1423-0410.2005.00631.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2005.00631.x</ArticleId><ArticleId IdType="pubmed">15877645</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Party of the British Committee for Standards in Haematology Transfusion Taskforce. Guidelines for the estimation of fetomaternal haemorrhage. London: British Society for Haematology; 2009.</Citation></Reference><Reference><Citation>Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">7636775</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011;342:d40
doi: 10.1136/bmj.d40
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d40</ArticleId><ArticleId IdType="pmc">PMC3230114</ArticleId><ArticleId IdType="pubmed">21300711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan BC, Jairath V, Dor&#xe9; CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15(1):139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022337</ArticleId><ArticleId IdType="pubmed">24755011</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence; 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">27905712</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):1&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448202</ArticleId></ArticleIdList></Reference><Reference><Citation>Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood J, Freemantle N, King M, Nazareth I. Trap of trends to statistical significance: likelihood of near significant P value becoming more significant with extra data. BMJ. 2014;348:g2215
doi: 10.1136/bmj.g2215
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g2215</ArticleId><ArticleId IdType="pubmed">24687314</ArticleId></ArticleIdList></Reference><Reference><Citation>Serious Hazards of Transfusion. Annual SHOT report 2015. Manchester: Serious Hazards of Transfusion; 2016.</Citation></Reference><Reference><Citation>de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109(2):99&#x2013;113. doi: 10.1111/vox.12265
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12265</ArticleId><ArticleId IdType="pubmed">25899660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33595867</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-0528</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>BJOG : an international journal of obstetrics and gynaecology</Title><ISOAbbreviation>BJOG</ISOAbbreviation></Journal><ArticleTitle>Contribution of blood detection of insulin-like growth factor binding protein-1 for the diagnosis of amniotic-fluid embolism: a retrospective multicentre cohort study.</ArticleTitle><Pagination><StartPage>1966</StartPage><EndPage>1973</EndPage><MedlinePgn>1966-1973</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1471-0528.16672</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess the contribution of maternal blood detection of IGFBP-1 for the diagnosis of amniotic-fluid embolism in clinical daily practice.</AbstractText><AbstractText Label="DESIGN">A retrospective multicentre cohort study.</AbstractText><AbstractText Label="SETTING">Three tertiary care obstetric units in France.</AbstractText><AbstractText Label="SAMPLE">Data of 86 women for whom amniotic-fluid embolism had been suspected and maternal serum detection of IGFBP-1 had been performed between 2011 and 2019 were analysed.</AbstractText><AbstractText Label="METHODS">The criteria defined by the United Kingdom Obstetric Surveillance System (UKOSS) were used for the retrospective diagnosis of amniotic-fluid embolism. The more structured definition proposed by the Society for Maternal-Fetal Medicine and the Amniotic Fluid Embolism Foundation (SMFM) was also used as secondary endpoint.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Agreements between biological and clinical assessments were tested. The performance of blood detection of IGFBP-1 for the diagnosis of amniotic-fluid embolism according to the UKOSS criteria, and to the SMFM definition, was also assessed.</AbstractText><AbstractText Label="RESULTS">There was only slight agreement between clinical and laboratory diagnosis of amniotic-fluid embolism (Cohen's Kappa coefficient: 0.04). Blood detection of IGFBP-1 had a sensitivity of 16%, a specificity of 88%, a positive and a negative likelihood ratio of 1.3 and 0.95, respectively, and a positive and a negative predictive value of 58 and 50%, respectively, for the diagnosis of amniotic-fluid embolism based on the UKOSS criteria. The use of the more structured SMFM definition of amniotic-fluid embolism did not substantially change the results.</AbstractText><AbstractText Label="CONCLUSION">These results question the usefulness of blood detection of IGFBP-1 for the early diagnosis of amniotic-fluid embolism in daily clinical practice.</AbstractText><AbstractText Label="TWEETABLE ABSTRACT">This retrospective multicentre study questions the contribution of IGFBP-1 detection for the diagnosis of AFE.</AbstractText><CopyrightInformation>&#xa9; 2021 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bouvet</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5900-4194</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care, Femme M&#xe8;re Enfant Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Lyon, Claude Bernard Lyon 1 University, Villeurbanne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APCSe VetAgro Sup UPSP 2016.A101, Marcy l'Etoile, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gariel</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care, Femme M&#xe8;re Enfant Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charvet</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care, Femme M&#xe8;re Enfant Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boisson-Gaudin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Fetal-Maternal Biology, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chassard</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care, Femme M&#xe8;re Enfant Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Lyon, Claude Bernard Lyon 1 University, Villeurbanne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APCSe VetAgro Sup UPSP 2016.A101, Marcy l'Etoile, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJOG</MedlineTA><NlmUniqueID>100935741</NlmUniqueID><ISSNLinking>1470-0328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C032231">IGFBP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018970">Insulin-Like Growth Factor Binding Protein 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BJOG. 2021 Nov;128(12):1974. doi: 10.1111/1471-0528.16833.</RefSource><PMID Version="1">34228892</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004619" MajorTopicYN="N">Embolism, Amniotic Fluid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018970" MajorTopicYN="N">Insulin-Like Growth Factor Binding Protein 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062145" MajorTopicYN="N">Maternal Serum Screening Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amniotic-fluid embolism</Keyword><Keyword MajorTopicYN="N">diagnostic</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">serum marker</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33595867</ArticleId><ArticleId IdType="doi">10.1111/1471-0528.16672</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Knight M, Bunch K, Tuffnel D, Shakespeare J, Kotnis R, Kenyon S, et&#xa0;al., editors, on behalf of MBRRACE-UK. Saving Lives, Improving Mothers&#x2019; Care - Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2015-2017. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2019.</Citation></Reference><Reference><Citation>Bonnet MP, Zlotnik D, Saucedo M, Chassard D, Bouvier-Colle MH, Deneux-Tharaux C. Maternal death due to amniotic fluid embolism: a national study in France. Anesth Analg 2018;126:175-82.</Citation></Reference><Reference><Citation>Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol 2015;125:5-12.</Citation></Reference><Reference><Citation>McDonnell N, Knight M, Peek MJ, Ellwood D, Homer CSE, McLintock C, et&#xa0;al. Amniotic fluid embolism: an Australian-New Zealand population-based study. BMC Pregnancy Childbirth 2015;15:352.</Citation></Reference><Reference><Citation>Sultan P, Seligman K, Carvalho B. Amniotic fluid embolism: update and review. Curr Opin Anaesthesiol 2016;29:288-96.</Citation></Reference><Reference><Citation>Pacheco LD, Saade G, Hankins GD, Clark SL. Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol 2016;215:B16-24.</Citation></Reference><Reference><Citation>Kanayama N, Tamura N. Amniotic fluid embolism: pathophysiology and new strategies for management. J Obstet Gynaecol Res 2014;40:1507-17.</Citation></Reference><Reference><Citation>Kanayama N, Yamazaki T, Naruse H, Sumimoto K, Horiuchi K, Terao T. Determining zinc coproporphyrin in maternal plasma - a new method for diagnosing amniotic fluid embolism. Clin Chem 1992;38:526-9.</Citation></Reference><Reference><Citation>Legrand M, Rossignol M, Dreux S, Luton D, Ventr&#xe9; C, Barranger E, et&#xa0;al. Diagnostic accuracy of insulin-like growth factor binding protein-1 for amniotic fluid embolism. Crit Care Med 2012;40:2059-63.</Citation></Reference><Reference><Citation>Rutanen EM, Bohn H, Seppala M. Radioimmunoassay of placental protein 12: levels in amniotic fluid, cord blood, and serum of healthy adults, pregnant women, and patients with trophoblastic disease. Am J Obstet Gynecol 1982;144:460-3.</Citation></Reference><Reference><Citation>Wang HS, Perry LA, Kanisius J, Iles RK, Holly JM, Chard T. Purification and assay of insulin-like growth factor-binding protein-1: measurement of circulating levels throughout pregnancy. J Endocrinol 1991;128:161-8.</Citation></Reference><Reference><Citation>Vandenbroucke JP, von Elm E, Altman DG, G&#xf8;tzsche PC, Mulrow CD, Pocock SJ, et&#xa0;al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297.</Citation></Reference><Reference><Citation>Van Cortenbosch B, Huel C, Houfflin Debarge V, Luton D, Lambaudie E, Porquet D, et&#xa0;al. Biologic tests for the diagnosis of amniotic fluid embolism. Ann Biol Clin (Paris) 2007;65:153-60.</Citation></Reference><Reference><Citation>Knight M, Berg C, Brocklehurst P, Kramer M, Lewis G, Oats J, et&#xa0;al. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth 2012;12:7.</Citation></Reference><Reference><Citation>Clark SL, Romero R, Dildy GA, Callaghan WM, Smiley RM, Bracey AW, et&#xa0;al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol 2016;215:408-12.</Citation></Reference><Reference><Citation>Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007;5:604-6.</Citation></Reference><Reference><Citation>Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.</Citation></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.</Citation></Reference><Reference><Citation>Stafford IA, Moaddab A, Dildy GA, Klassen M, Belfort MA, Romero R, et&#xa0;al. Evaluation of proposed criteria for research reporting of amniotic fluid embolism. Am J Obstet Gynecol 2019;220:285-7.</Citation></Reference><Reference><Citation>Ponzio-Klijanienko A, Vincent-Rohfritsch A, Girault A, Le Ray C, Goffinet F, Bonnet MP. Evaluation of the 4 diagnosis criteria proposed by the SMFM and the AFE Foundation for amniotic fluid embolism in a monocentric population. J Gynecol Obstet Hum Reprod 2020;49:101821.</Citation></Reference><Reference><Citation>Kramer MS, Rouleau J, Baskett TF, Joseph KS. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006;368:1444-8.</Citation></Reference><Reference><Citation>Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol 2008;199:49.e1-8.</Citation></Reference><Reference><Citation>Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG 2016;123:100-9.</Citation></Reference><Reference><Citation>Clark SL. Amniotic fluid embolism. Obstet Gynecol 2014;123:337-48.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29318985</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2046-4924</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Health technology assessment (Winchester, England)</Title><ISOAbbreviation>Health Technol Assess</ISOAbbreviation></Journal><ArticleTitle>A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>88</EndPage><MedlinePgn>1-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3310/hta22020</ELocationID><Abstract><AbstractText Label="BACKGROUND">Caesarean section is associated with blood loss and maternal morbidity. Excessive blood loss requires transfusion of donor (allogeneic) blood, which is a finite resource. Cell salvage returns blood lost during surgery to the mother. It may avoid the need for donor blood transfusion, but reliable evidence of its effects is lacking.</AbstractText><AbstractText Label="OBJECTIVES">To determine if routine use of cell salvage during caesarean section in mothers at risk of haemorrhage reduces the rates of blood transfusion and postpartum maternal morbidity, and is cost-effective, in comparison with standard practice without routine salvage use.</AbstractText><AbstractText Label="DESIGN">Individually randomised controlled, multicentre trial with cost-effectiveness analysis. Treatment was not blinded.</AbstractText><AbstractText Label="SETTING">A total of 26 UK obstetric units.</AbstractText><AbstractText Label="PARTICIPANTS">Out of 3054 women recruited between June 2013 and April 2016, we randomly assigned 3028 women at risk of haemorrhage to cell salvage or routine care. Randomisation was stratified using random permuted blocks of variable sizes. Of these, 1672 had emergency and 1356 had elective caesareans. We excluded women for whom cell salvage or donor blood transfusion was contraindicated.</AbstractText><AbstractText Label="INTERVENTIONS">Cell salvage (intervention) versus routine care without salvage (control). In the intervention group, salvage was set up in 95.6% of the women and, of these, 50.8% had salvaged blood returned. In the control group, 3.9% had salvage deployed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Primary - donor blood transfusion. Secondary - units of donor blood transfused, time to mobilisation, length of hospitalisation, mean fall in haemoglobin, fetomaternal haemorrhage (FMH) measured by Kleihauer-Betke test, and maternal fatigue. Analyses were adjusted for stratification factors and other factors that were believed to be prognostic a priori. Cost-effectiveness outcomes - costs of resources and service provision taking the UK NHS perspective.</AbstractText><AbstractText Label="RESULTS">We analysed 1498 and 1492 participants in the intervention and control groups, respectively. Overall, the transfusion rate was 2.5% in the intervention group and 3.5% in the control group [adjusted odds ratio (OR) 0.65, 95% confidence interval (CI) 0.42 to 1.01; <i>p</i>&#x2009;=&#x2009;0.056]. In a planned subgroup analysis, the transfusion rate was 3.0% in the intervention group and 4.6% in the control group among emergency caesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 1.8% in the intervention group and 2.2% in the control group among elective caesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83) (interaction <i>p</i>&#x2009;=&#x2009;0.46, suggesting that the difference in effect between subgroups was not statistically significant). Secondary outcomes did not differ between groups, except for FMH, which was higher under salvage in rhesus D (RhD)-negative women with RhD-positive babies (25.6% vs. 10.5%, adjusted OR 5.63, 95% CI 1.43 to 22.14; <i>p</i>&#x2009;=&#x2009;0.013). No case of amniotic fluid embolism was observed. The additional cost of routine cell salvage during caesarean was estimated, on average, at &#xa3;8110 per donor blood transfusion avoided.</AbstractText><AbstractText Label="CONCLUSIONS">The modest evidence for an effect of routine use of cell salvage during caesarean section on rates of donor blood transfusion was associated with increased FMH, which emphasises the need for adherence to guidance on anti-D prophylaxis. We are unable to comment on long-term antibody sensitisation effects. Based on the findings of this trial, cell salvage is unlikely to be considered cost-effective.</AbstractText><AbstractText Label="FUTURE WORK">Research into risk of alloimmunisation among women exposed to cell salvage is needed.</AbstractText><AbstractText Label="TRIAL REGISTRATION">Current Controlled Trials ISRCTN66118656.</AbstractText><AbstractText Label="FUNDING">This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol. 22, No. 2. See the NIHR Journals Library website for further project information.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Khalid S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Selwyn Crawford Department of Anaesthetics, Birmingham Women's Hospital, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allard</LastName><ForeName>Shubha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Haematology, NHS Blood and Transplant, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrench</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Anaesthetics, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Health Economics Unit, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLoughlin</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Economics Unit, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beresford</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geoghegan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Selwyn Crawford Department of Anaesthetics, Birmingham Women's Hospital, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catling</LastName><ForeName>Sue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthetics, Singleton Hospital, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Vicki A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayuk</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Women's Services, Royal Victoria Infirmary, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robson</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao-Smith</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Perioperative, Critical Care and Trauma Trials Group, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogg</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Health Economics Unit, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanz</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodds</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN66118656</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>10/57/32</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Technol Assess</MedlineTA><NlmUniqueID>9706284</NlmUniqueID><ISSNLinking>1366-5278</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006295" MajorTopicYN="N">Health Resources</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057725" MajorTopicYN="N">Operative Blood Salvage</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013673" MajorTopicYN="N">Technology Assessment, Biomedical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29318985</ArticleId><ArticleId IdType="pmc">PMC5776407</ArticleId><ArticleId IdType="doi">10.3310/hta22020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22017328</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1619-3997</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of perinatal medicine</Title><ISOAbbreviation>J Perinat Med</ISOAbbreviation></Journal><ArticleTitle>Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>49</EndPage><MedlinePgn>43-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/JPM.2011.109</ELocationID><ELocationID EIdType="pii" ValidYN="Y">/j/jpme.2012.40.issue-1/jpm.2011.109/jpm.2011.109.xml</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effectiveness of human recombinant activated factor VII (rhFVIIa, NovoSeven) in avoiding hysterectomy postpartum in the management of severe postpartum hemorrhage (PPH).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a prospective cohort study at our university tertiary care center. Patients with severe post partum hemorrhage (blood loss &gt;2000 mL) and failed medical and uterus-preserving surgical management, were treated with intravenous bolus administration of rhVIIa. Main outcome measures were cessation of bleeding, postpartum hysterectomy and thromboembolic events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 20/22 patients included, PPH was caused primarily by uterine atony, including 7 (32%) with additional lower genital tract lesion; in two women, it was due to pathologic placentation (placenta increta, 9%). One case of amniotic fluid embolism and one woman with uterine inversion were included. Recombinant hFVIIa was successful in stopping the PPH and in preventing a hysterectomy in 20/22 women (91%). The remaining two patients with persistent bleeding despite rhFVIIa treatment, who underwent postpartum hysterectomy, had placenta increta. No thromboembolic event was noticed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study describes the largest single center series of rhFVIIa treatment for fertility preservation in severe postpartum hemorrhage published to date. Our data suggest that administration of rhFVIIa is effective in avoiding postpartum hysterectomy after conservative medical and surgical measures have failed. Although randomized studies are lacking, rhFVIIa should be considered as a second-line therapeutic option of life-threatening postpartal bleeding, in particular if preservation of fertility is warranted and hysterectomy is to be avoided.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Alexander W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Inselspital University Hospital, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raio</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Alberio</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ghezzi</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Surbek</LastName><ForeName>Daniel V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Perinat Med</MedlineTA><NlmUniqueID>0361031</NlmUniqueID><ISSNLinking>0300-5577</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>AC71R787OV</RegistryNumber><NameOfSubstance UI="C103587">recombinant FVIIa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.21</RegistryNumber><NameOfSubstance UI="D015942">Factor VIIa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015942" MajorTopicYN="N">Factor VIIa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059247" MajorTopicYN="N">Fertility Preservation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006403" MajorTopicYN="N">Hematologic Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007044" MajorTopicYN="N">Hysterectomy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006473" MajorTopicYN="N">Postpartum Hemorrhage</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22017328</ArticleId><ArticleId IdType="doi">10.1515/JPM.2011.109</ArticleId><ArticleId IdType="pii">/j/jpme.2012.40.issue-1/jpm.2011.109/jpm.2011.109.xml</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">30614315</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4954</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>17</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of maternal-fetal &amp; neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians</Title><ISOAbbreviation>J Matern Fetal Neonatal Med</ISOAbbreviation></Journal><ArticleTitle>The use of Zhukovsky vaginal and intrauterine balloons to improve the outcome of postpartum hysterectomies in patients with severe bleeding.</ArticleTitle><Pagination><StartPage>2955</StartPage><EndPage>2960</EndPage><MedlinePgn>2955-2960</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14767058.2019.1566309</ELocationID><Abstract><AbstractText><b>Aim:</b> To assess the efficacy of a Zhukovsky obstetric double balloon for improving outcomes in women undergoing hysterectomy for postpartum hemorrhage.<b>Materials and methods:</b> This was a randomized controlled study. Participants were divided into two groups to undergo insertion of a Zhukovsky obstetric double balloon prior to hysterectomy (<i>n</i>&#x2009;=&#x2009;16) or conventional hysterectomy (<i>n</i>&#x2009;=&#x2009;25).<b>Results:</b> The main reasons for major obstetric hemorrhage were placenta accreta (53.6%), uterine atony (26.8%), uteroplacental apoplexy (14.6%), and amniotic fluid embolism (4.8%). The use of a Zhukovsky obstetric double balloon during postpartum hysterectomy was associated with a 1.7-fold reduction in blood loss and a 2.3-fold reduction in blood loss &gt; 2000&#x2009;ml compared with conventional hysterectomy.<b>Conclusion:</b> The use of a Zhukovsky obstetric double balloon represents a potent tool for improvement of immediate outcomes of hysterectomy in women with severe postpartum bleeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barinov</LastName><ForeName>Sergey V</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0002-0357-7097</Identifier><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medjannikova</LastName><ForeName>Irina V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirskaya</LastName><ForeName>Yuliya I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuprinin</LastName><ForeName>Vladimir D</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Ministry of Health of Russia, National Medical Research Center of Obstetrics, Gynecology and Perinatology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khilkevich</LastName><ForeName>Elena G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Ministry of Health of Russia, National Medical Research Center of Obstetrics, Gynecology and Perinatology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelyeva</LastName><ForeName>Irina V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamina</LastName><ForeName>Inna V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borisova</LastName><ForeName>Anna V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazareva</LastName><ForeName>Oksana V</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Russian Ministry of Health, Federal State Budget Educational Institution of Higher Education Omsk State Medical University, Omsk, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Matern Fetal Neonatal Med</MedlineTA><NlmUniqueID>101136916</NlmUniqueID><ISSNLinking>1476-4954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007044" MajorTopicYN="N">Hysterectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010921" MajorTopicYN="Y">Placenta Accreta</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006473" MajorTopicYN="Y">Postpartum Hemorrhage</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014593" MajorTopicYN="Y">Uterine Inertia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">Zhukovsky intrauterine balloon</Keyword><Keyword MajorTopicYN="N">Zhukovsky vaginal balloon</Keyword><Keyword MajorTopicYN="N">cesarean section</Keyword><Keyword MajorTopicYN="N">delivery</Keyword><Keyword MajorTopicYN="N">hysterectomy</Keyword><Keyword MajorTopicYN="N">obstetric hemorrhage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30614315</ArticleId><ArticleId IdType="doi">10.1080/14767058.2019.1566309</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>